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INTRODUCTION 
 
 The method by which a drug is delivered can have a significant effect on 
its efficacy. Some drugs have an optimum concentration range within which 
maximum benefit is derived, and concentrations above or below this range can be 
toxic or produce no therapeutic benefit at all. On the other hand, the very slow 
progress in the efficacy of the treatment of severe diseases, has suggested a growing 
need for a multidisciplinary approach to the delivery of therapeutics to targets in 
tissues. (R.R. Bhagwat et. al 2013) 
From this, new ideas on controlling the pharmacokinetics, 
pharmacodynamics, non-specific toxicity, immunogenicity, biorecognition, and 
efficacy of drugs were generated. These new strategies, often called drug delivery 
systems (DDS), which are based on interdisciplinary approaches that combine 
polymer science, pharmaceutics, bioconjugate chemistry, and molecular biology. 
To minimize drug degradation and loss, to prevent harmful side-effects and to 
increase drug bioavailability and the fraction of the drug accumulated in the 
required zone, various drug delivery and drug targeting systems are currently under 
development. Controlled and Novel Drug Delivery which was only a dream or at 
best a possibility is now a reality. During the last decade and half pharmaceutical 
and other scientists have carried out extensive and intensive investigations in this 
field of drug research. 
Among drug carriers one can name soluble polymers, microparticles made 
of insoluble or biodegradable, natural and synthetic polymers, microcapsules, cells, 
cell ghosts, lipoproteins, liposomes, and micelles. The carriers can be made slowly 
degradable, stimuli-reactive (e.g., pH- or temperature-sensitive), and even targeted 
(e.g., by conjugating them with specific antibodies against certain characteristic 
components of the area of interest). Targeting is the ability to direct the drug-loaded 
system to the site of interest. Two major mechanisms can be distinguished for 
addressing the desired sites for drug release: 
 
 Passive and; 
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 Active targeting  
An example of passive targeting is the preferential accumulation of 
chemotherapeutic agents in solid tumours as a result of the enhanced vascular 
permeability of tumour tissues compared with healthy tissue. A strategy that could 
allow active targeting involves the surface functionalization of drug carriers with 
ligands that are selectively recognized by receptors on the surface of the cells of 
interest. Since ligand–receptor interactions can be highly selective, this could allow 
a more precise targeting of the site of interest. 
 
Figure 1: Mechanism of drug delivery system (R.R. Bhagwat , et. al .2013) 
 
 
Delivering therapeutic compound to the target site is a major problem in 
treatment of many diseases. A conventional application of drugs is characterized by 
limited effectiveness, poor bio distribution, and lack of selectivity. These 
limitations and drawback can be overcome by controlling drug delivery. In 
controlled drug delivery systems (CDDS) the drug is transported to the place of 
action, thus, its influence on vital tissues and undesirable side effects can be 
minimized. In addition, DDS protects the drug from rapid degradation or clearance 
and enhances drug concentration in target tissues, therefore, lower doses of drug are 
required. This modern form of therapy is especially important when there is a 
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discrepancy between a dose or concentration of a drug and its therapeutic results or 
toxic effects. 
Cell-specific targeting can be achieved by attaching drugs to individually 
designed carriers. Recent developments in nanotechnology have shown that 
nanoparticles (structures smaller than 100 nm in at least one dimension) have a great 
potential as drug carriers. Due to their small sizes, the nanostructures exhibit unique 
physicochemical and biological properties (e.g., an enhanced reactive area as well 
as an ability to cross cell and tissue barriers) that make them a favourable material 
for biomedical applications.  
The primary goals for research of nano-bio-technologies in drug delivery 
include: 
 More specific drug targeting and delivery, 
 Reduction in toxicity while maintaining therapeutic effects, 
 Greater safety and biocompatibility, and 
 Faster development of new safe medicines. 
 
The main issues in the search for appropriate carriers as drug delivery 
systems are basic prerequisites for design of new materials. They comprise 
knowledge on  
 drug incorporation and release,  
 formulation stability and shelf life  
 biocompatibility, 
 bio distribution and targeting 
  functionality.  
In addition, when used solely as carrier the possible adverse effects of 
residual material after the drug delivery should be considered as well. In this 
respect, biodegradable nanoparticles with a limited life span if therapeutically 
needed would be optimal. 
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Targeted drug delivery system 
The concept of designing targeted delivery system has been originated from 
the Paul Ehrlich, who was a microbiologist, proposed the idea of drug delivery in 
the form of magic bullet. Targeted drug delivery means accumulation of 
pharmacologically active moiety at desired target in therapeutic concentration at the 
same restricting its access to normal cellular lining, thus minimizing therapeutic 
index. The drug can be targeted to intracellular sites, virus cells, bacteria cell and 
parasites using different scientific strategies have proven highly effective.  The 
minimum distribution of the parent drug to the non-target cells with higher and 
effective concentration at the targeted site certainly maximize the benefits of 
targeted drug delivery. (E. Bhargav et.al 2013) 
            Targeted delivery can be actively or passively achieved. Active targeting 
requires the therapeutic agent to be achieved by conjugating the therapeutic agent 
or carrier system to a tissue or cell-specific ligand (Lamprecht et. al., 2001). Passive 
targeting is achieved by incorporating the therapeutic agent into a macromolecule 
or nanoparticle that passively reaches the target organ. Drugs encapsulated in 
nanoparticles or drugs coupled to macromolecules can passively target tumours 
through the EPR effect. Alternatively, catheters can be used to infuse nanoparticles 
to the target organ or tissues. For example, localized delivery of drug-bearing 
nanoparticles to sites of vascular restenosis may be useful for providing sustained 
drug release at specific sites on the arterial wall (Maeda, 2001; Sahoo et. al., 2002). 
 
 
 
Brain targeting drug delivery system 
In the central nervous system, targeted action can be achieved by direct 
administration of the drugs in to the CNS. Blood brain barrier can considerably 
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impair the effect of the large number of drugs (e.g.    antibiotics, antineoplastic 
agents and Neuropeptides-CNS stimulant drug) because of its obstinate hindrance 
affect.  From some recent studies, it has been represented that the blood  
brain barrier is usually does not cross by almost 100% of large molecule drugs  
and 98% of small molecule  drugs Presently, numerous approaches with enhanced 
pharmacodynamics effects, have been developed for the treatment of brain 
disorders. Drug discovery and drug delivery technologies are the two main fields 
where advancement is required for drug delivery to the brain.  Nanoparticles drug 
delivery system (NDDS) is one of the advanced technology that can be utilized to 
deliver drug molecules directly into the brain and proved to be very effective against 
several CNS disorders. (Yasir Mohamed et. al 2015) 
 
Figure 2: Drug Targeting Technology 
 
 
Nanoparticles  
Nanoparticles (NPs) containing encapsulated, dispersed, absorbed or 
conjugated drugs have unique characteristics that can lead to enhanced performance 
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in a variety of dosage forms. The aims for nanoparticle entrapment of drugs are 
either enhanced delivery to, or uptake by, target cells and/or a reduction in the 
toxicity of the free drug to non-target organs. Both situations will result in an 
increase of therapeutic index, the margin between the doses resulting in a 
therapeutic efficacy (e.g. tumour cell death) and toxicity to other organ systems. For 
these aims, creation of long-lived and target-specific nanoparticles is needed. For 
these aims, creation of long-lived and target-specific nanoparticles is needed.  
 
When formulated correctly, drug particles are resistant to settling and can 
have higher saturation solubility, rapid dissolution and enhanced adhesion to 
biological surfaces, thereby providing rapid onset of therapeutic action and 
improved bioavailability. In addition, the clear majority of molecules in a 
nanostructure reside at the particle surface, which maximizes the loading and 
delivery of cargos, such as therapeutic drugs, proteins and polynucleotides, to 
targeted cells and tissues. Highly efficient drug delivery, based on nanomaterials, 
could potentially reduce the drug dose needed to achieve therapeutic benefit, which, 
in turn, would lower the cost and/or reduce the side effects associated with drugs. 
Furthermore, NP size and surface characteristics can be easily manipulated to 
achieve both passive and active drug targeting. Site-specific targeting can be 
achieved by attaching targeting ligands, such as antibodies or aptamers, to the 
surface of particles, or by using guidance in the form of magnetic NPs. NPs can also 
control and sustain release of a drug during transport to, or at, the site of localization, 
altering drug distribution and subsequent clearance of the drug to improve 
therapeutic efficacy and reduce side effects. 
 
 
The key advantages of nanoparticles are  
(1)  improved bioavailability by enhancing aqueous solubility, 
Introduction 
 
 
Department of  Pharmaceutics  7 
 
(2)  increasing resistance time in the body (increasing half-life for 
 clearance/increasing specificity for its cognate receptors 
(3)  targeting drug to specific location in the body (its site of action).  
 
This results in concomitant reduction in quantity of the drug required and 
dosage toxicity, enabling the safe delivery of toxic therapeutic drugs and protection 
of non-target tissues and cells from severe side effect. It is increasingly used in 
different applications, including drug carrier systems and to pass organ barriers such 
as the blood-brain barrier, cell membrane etc. They are based on biocompatible  
lipid and provide sustained effect by either diffusion or dissolution. (Wim H De 
Jong et alet.al 2008) 
 
History of nanoparticles 
The history of nanoparticles is older than the nanotechnology. The first 
known use of nanoparticles, made by artisans in the 9th century in Mesopotamia to 
create a shiny effect on the pot surfaces. Artisans Artisans created these 
nanoparticles by adding salts of copper and silver and oxides them with clay, 
vinegar and ochre, on the surface of the cover which has been made before. After 
creation, the object was put into a special oven and heated until it reaches about  
600 °C in a decreasing atmosphere. As temperature increases in the oven, silver and 
copper ions slide to the outer layers of glitter.  
 
However, Michael Faraday was the one who made the first scientific 
description about nanoparticles. He pointed out the optical proper ties of 
nanometascale metals in his classic 1857 paper. 
 
 
Use of nanoparticle in medicine and biology 
In medicine and biology, nanoparticles are one of the basic things for 
applications. The main reason is their size and high ratio of surface area to mass. 
The most known applications are;  
Formatted: Font: 7 pt, Complex Script Font: 7 pt
Formatted: Font: 8 pt, Complex Script Font: 8 pt
Formatted: Font: 1 pt, Complex Script Font: 1 pt
Introduction 
 
 
Department of  Pharmaceutics  8 
 
 Fluorescent biological labels,  
 Drug and gene delivery  
 Bio detection of pathogens  
 Detection of proteins  
 Probing of DNA structure  
 Tissue engineering  
 Tumour destruction via heating (hyperthermia) (Wim H De Jong et. al 2008) 
 
Drug release from nanoparticles (Sagar R. Mudshinge et alet.al 2011) 
Nanoparticles are coated with polymers that releases the drug by controlled 
diffusion or erosion from the core across the polymeric membrane or matrix. The 
membrane coating acts as a barrier to release, therefore, the solubility and 
diffusivity of drug in polymer membrane becomes the determining factor in drug 
release. The release rate is affected by ionic interaction between the drug and 
addition of auxiliary ingredients. When the drug is involved in interaction with 
auxiliary ingredients to form a less water soluble complex, then the drug release can 
be very slow with almost no burst release effect. 
 
For developing a nanoparticulate system the two important factors to be 
considered are drug release and polymer biodegradation. Drug release rate depends 
on  
(1)  solubility of drug, 
 (2)  desorption of the surface bound/ adsorbed drug,  
(3)  drug diffusion through the nanoparticle matrix 
(4)  nanoparticle matrix erosion/degradation and  
(5)  combination of erosion/diffusion process.  
Thus solubility, diffusion and biodegradation of the matrix materials govern 
the release process. 
Advantages of Nanoparticles (Yasir Mohamed et alet.al 2015) 
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 Drug carrying capacity is high 
 Nanoparticles releases the drug in sustained manner 
 Drug Having extended time of circulation/show stability in bloodstream 
Disadvantage of Nanoparticles 
 Manufacturing cost is very high for this drug delivery system. 
 May possibly cause allergic Reactions 
 Nanoparticles may cause some toxic/unwanted reactions due to the over use 
 of polyvinyl alcohol in their formulation 
Characteristics Important for Drug Delivery using Nanoparticles 
 Particle size 
Particle size and size distribution are the most important characteristics of 
nanoparticles. They determine the in vivo distribution, biological fate, toxicity, and 
targeting ability of these delivery systems. In addition, they can influence drug 
loading, drug release, and stability of nanoparticles. Many studies have 
demonstrated that nanoparticles have several advantages over microparticles 
(Panyam and Labhasetwar, 2003). Generally, nanoparticles have relatively high cell 
uptake when compared to microparticles and are available to a wider range of 
cellular and intracellular targets due to their small size and mobility. Nanoparticles 
can cross the blood-brain barrier following the opening of endothelium tight 
junctions by hyper-osmotic mannitol, which may provide sustained delivery of 
therapeutic agents for difficult-to-treat diseases like brain tumours (Kroll et al., 
1998). Tween 80-coated nanoparticles have been shown to cross the blood-brain 
barrier as well (Kreuter et alet. al., 2003). Submicron nanoparticles, but not larger 
microparticles, are taken up by most cell types (Zauner et alet. al., 2001). Indeed, 
100 nm nanoparticles had a 2.5-fold greater uptake rate than 1 μm microparticles, 
and a 6-fold greater uptake than 10 μm microparticles by Caco-2 cells (Desai et aet. 
all., 1997).  
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Drug release also is affected by particle size. Smaller particles have a larger surface 
area-to-volume ratio; therefore, most of the drug associated with small particles 
would be at or near the particle surface, leading to faster drug release. In contrast, 
larger particles have large cores, which allow more drug to be encapsulated per 
particle and give slower release (Redhead et.  all., , 2001). Thus, control of particle 
size provides a means of tuning drug release rates. 
 Surface properties of nanoparticles 
The association of a drug to conventional carriers leads to modification of 
the drug bio distribution profile, as it is mainly delivered to the mononuclear 
phagocyte system (MPS) such as liver, spleen, lungs and bone marrow. 
Nanoparticles can be recognized by the host immune system when intravenously 
administered and cleared by phagocytes from the circulation (Muller et. al., 1996). 
Apart from the size of nanoparticles, nanoparticle hydrophobicity determines the 
level of blood components (e.g., opsonins) that bind this surface. Hence, 
hydrophobicity influences the in vivo fate of nanoparticles (Brigger et. al., 
2002; Muller et alet.al., 1996). Indeed, once in the blood stream, surface non-
modified nanoparticles (conventional nanoparticles) are rapidly opsonized and 
massively cleared by the MPS (Grislain et. al., 1983). 
 
To increase the likelihood of success in drug targeting, it is necessary to 
minimize the opsonisation and prolong the circulation of nanoparticles in vivo. This 
can be achieved by coating nanoparticles with hydrophilic polymers/surfactants or 
formulating nanoparticles with biodegradable copolymers with hydrophilic 
characteristics, e.g., polyethylene glycol (PEG), polyethylene oxide, poloxamer, 
poloxamer, and polysorbate 80 (Tween 80). Studies show that PEG on nanoparticle 
surfaces prevents opsonization by complement and other serum factors. PEG 
molecules with brush-like and intermediate configurations reduced phagocytosis 
and complement activation, whereas surfaces comprised of PEG with mushroom-
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like structures were potent complement activators and favoured phagocytosis 
(Bhadra et.  al., 2002; Olivier, 2005). 
 
The zeta potential of a nanoparticle is commonly used to characterize the 
surface charge property of nanoparticles (Couvreur et.  al., 2002). It reflects the 
electrical potential of particles and is influenced by the composition of the particle 
and the medium in which it is dispersed. Nanoparticles with a zeta potential above 
± 30 mV have been shown to be stable in suspension, as the surface charge prevents 
aggregation of the particles. The zeta potential also can be used to determine 
whether a charged active material is encapsulated within the centre of the 
nanoparticle or on the surface. 
 
 
 Drug loading 
A successful Nano delivery system should have a high drug-loading 
capacity, thereby reducing the quantity of matrix materials for administration. Drug 
loading can be accomplished by two methods. The incorporation method requires 
the drug to be incorporated at the time of nanoparticle formulation. The 
adsorption/absorption methods call for absorption of the drug after nanoparticle 
formation; this is achieved by incubating the nano-carrier with a concentrated drug 
solution. Drug loading and entrapment efficiency depend on drug solubility in the 
excipient matrix material (solid polymer or liquid dispersion agent), which is related 
to the matrix composition, molecular weight, drug-polymer interactions, and the 
presence of end functional groups (i.e., ester or carboxyl) in either the drug or matrix 
(Govender et alet.al., 1999; Govender et alet.al., 2000; Panyam et. al., 2004). A 
polymer of choice for some nanoparticle formulations is PEG, which has little or 
no effect on drug-loading and interactions (Peracchia et.  al., 1997). In addition, the 
macromolecules, drugs or protein encapsulated in nanoparticles show the greatest 
loading efficiency when they are loaded at or near their isoelectric point (pI)  
(Calvo et alet. al., 1997). For small molecules, studies show the use of ionic 
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interaction between the drug and matrix materials can be very effective in 
increasing drug-loading (Chen et.  al., 1994; Chen et.  al., 2003). 
 
 Drug release 
It is important to consider both drug release and polymer biodegradation 
when developing a nanoparticulate delivery system. In general, the drug release rate 
depends on: (1) drug solubility; (2) desorption of the surface-bound or adsorbed 
drug; (3) drug diffusion through the nanoparticle matrix; (4) nanoparticle matrix 
erosion or degradation; and (5) the combination of erosion and diffusion processes. 
Hence, solubility, diffusion, and biodegradation of the particle matrix govern the 
release process. 
 
 
In the case of nanospheres, where the drug is uniformly distributed, drug 
release occurs by diffusion or erosion of the matrix. If the diffusion of the drug is 
faster than matrix erosion, then the mechanism of release is largely controlled by a 
diffusion process. The rapid, initial release, or ‘burst’, is mainly attributed to weakly 
bound or adsorbed drug to the relatively large surface of nanoparticles (Magenheim 
et. al., 1993). It is evident that the method of incorporation influences the release 
profile. If the drug is loaded by the incorporation method, then the system has a 
relatively small burst effect and sustained release characteristics (Fresta et alet.al., 
1995). If the nanoparticle is coated by polymer, the release is then controlled by 
diffusion of the drug from the polymeric membrane. 
 
Membrane coating acts as a drug release barrier; therefore, drug solubility 
and diffusion in or across the polymer membrane becomes a determining factor in 
drug release. Furthermore, the release rate also can be affected by ionic interactions 
between the drug and auxiliary ingredients. When the entrapped drug interacts with 
auxiliary ingredients, a less water soluble complex can form, which can slow the 
drug release – having almost no burst release effect (Chen et alet.al., 1994). 
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Whereas if the addition of auxiliary ingredients, e.g., ethylene oxide-propylene 
oxide block copolymer  to chitosan, reduces the interaction of the drug with the 
matrix material due to competitive electrostatic interaction of PEO-PPO with 
chitosan, then an increase in drug release could be achieved (Calvo et al., 1997). 
Various methods can be used to study the release of drug from the nanoparticle: (1) 
side-by-side diffusion cells with artificial or biological membranes; (2) dialysis bag 
diffusion; (3) reverse dialysis bag diffusion;; (4) agitation followed by 
ultracentrifugation/ centrifugation; or (5) ultra-filtration. Usually the release study 
is carried out by controlled agitation followed by centrifugation. Due to the time-
consuming nature and technical difficulties encountered in the separation of 
nanoparticles from release media, the dialysis technique is generally preferred. 
However, these methods prove difficult to replicate and scale-up for industrial use. 
 
 
TYPES OF NANOPARTICLES 
Extensive libraries of nanoparticles, composed of an assortment of different 
sizes, shapes, and materials, and with various chemical and surface properties, have 
already been constructed. This field is rapidly growing and these continue to 
supplement these huge collections with new contributions. Some of the classes of 
nanoparticles are listed below 
Fullerenes 
A fullerene is any molecule composed entirely of carbon. These are in the 
form of hollow sphere, ellipsoid, or tube. Fullerenes are similar in structure to the 
graphite, which is composed of stacked grapheme sheets of linked hexagonal rings, 
additionally they may also contain pentagonal (or sometimes heptagonal) rings to 
give potentially porous molecules (Holister et al., 2003). A spherical fullerene 
composed of less than 300 carbon atoms are commonly known as endohedral 
fullerenes and include the most common fullerene. Mega tubes are larger in 
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diameter than nanotubes and prepared with walls of different thickness which is 
potentially used for the transport of a variety of molecules of different sizes 
(Mitchell et alet al., 2001).  
 
 
Solid lipid nanoparticles 
Solid lipid nanoparticles comprise of lipids that are in solid phase at room 
temperature and surfactants for emulsification. SLNs offer unique properties such 
as small size, large surface area, high drug loading, the interaction of phases at the 
interfaces, and are attractive for their potential to improve performance of 
pharmaceuticals, nutraceuticals and other materials. Solid lipids utilized in SLN 
formulations include fatty acids, triglycerin, steroids (e.g. cholesterol), partial 
glycerides and waxes. Several types of surfactants are commonly used as 
emulsifiers to stabilize lipid dispersion, including soybean lecithin, 
phosphatidylcholine, poloxamer 188, sodium cholate, and sodium glycocholate.. 
SLNs possess a better stability and ease of upgradability to production scale as 
compared to liposomes. This property may be very important for many modes of 
targeting. 
 
Liposomes 
Liposomes are vesicular structures with an aqueous core surrounded by a 
hydrophobic lipid bilayer, created by the extrusion of phospholipids. Solutes, such 
as drugs, in the core cannot pass through the hydrophobic bilayer however 
hydrophobic molecules can be absorbed into the bilayer, enabling the liposome to 
carry both hydrophilic and hydrophobic molecules. The lipid bilayer of liposomes 
can fuse with other bilayers such as the cell membrane, which promotes release of 
its contents, making them useful for drug delivery and cosmetic delivery 
applications. 
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Nanostructured lipid carriers (NLC) 
Nanostructured Lipid Carriers are produced from blend of solid and liquid 
lipids, but particles are in solid state at body temperature. Lipids are versatile 
molecules that may form differently structured solid matrices, such as the 
nanostructured lipid carriers (NLC) and the lipid drug conjugate nanoparticles 
(LDC), that have been created to improve drug loading capacity. NLCs can 
generally be applied where solid nanoparticles possess advantages for the delivery 
of drugs. Major application areas in pharmaceutics are topical drug delivery, oral 
and parenteral (subcutaneous or intramuscular and intravenous) route. They also 
have applications in cosmetics, food and agricultural products. These have been 
utilized in the delivery of anti-inflammatory compounds, cosmetic preparation, 
topical cortico therapy and also increases bioavailability and drug loading capacity. 
 
 
 
Nano shells 
Nano shells are also notorious as core-shells, Nano shells are spherical cores 
of a compound (concentric particles) surrounded by a shell or outer coating of thin 
layer of another material, which is a few 1–20 nm nanometres thick. Nano shell 
particles are highly functional materials show modified and improved properties 
than their single component counterparts or nanoparticles of the same size. Their 
properties can be modified by changing either the constituting materials or core-to-
shell ratio. 
Dendrimers 
Dendrimers are unimolecular, monodisperse, micellar nanostructures, 
around 20 nm in size, with a well-defined, regularly branched symmetrical structure 
and a high density of functional end groups at their periphery. The structure of 
Formatted: Space Before:  12 pt
Formatted: Space Before:  12 pt
Introduction 
 
 
Department of  Pharmaceutics  16 
 
dendrimers consists of three distinct architectural regions as a focal moiety or a 
core, layers of branched repeat units emerging from the core, and functional end 
groups on the outer layer of repeat units. They are known to be robust, covalently 
fixed, three dimensional structures possessing both a solvent-filled interior core 
(nanoscale container) as well as a homogenous, mathematically defined, exterior 
surface functionality. 
 
 
 
Quatom dots 
The quantum dots are semiconductor nanocrystals and coreshell 
nanocrystals containing interface between different semiconductor materials. The 
size of quantum dots can be continuously tuned from 2 to 10 nm, which, after 
polymer encapsulation, generally increases to 5–20 nm in diameter. Particles 
smaller than 5 nm are quickly cleared by renal filtration. 
 
 
Biodegradable nanoparticles 
Biodegradable nanoparticles have been used for site-specific delivery of 
drugs, vaccines and various other biomolecules. A few of the most extensively used 
biodegradable polymer matrices for preparation of nanoparticles are 
 
 Gelatin  
Gelatin is extensively used in food and medical products and is a nontoxic 
alternative. Gelatin NPs are very efficient in delivery and controlled release of the 
drugs. They are nontoxic, biodegradable, bioactive and inexpensive. Gelatin is a 
poly-ampholyte consisting of both cationic and anionic groups along with a 
hydrophilic group. It is known that the mechanical properties such as swelling 
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behavior and thermal properties of gelatin NPs depend significantly on the degree 
of cross-linking between cationic and anionic groups. These properties of gelatin 
can be manipulated to prepare desired type of NPs from gelatin. Gelatin 
nanoparticles can be prepared by the desolvation/coacervation or emulsion 
methods. 
  
 Chitosan 
Chitosan is a modified natural carbohydrate polymer prepared by the partial 
N-deacetylation of the crustacean-derived natural biopolymer chitin. There are at 
least four methods reported for the preparation of chitosan nanoparticles. The four 
methods are ionotropic gelation, micro emulsion, emulsification solvent diffusion 
and polyelectrolyte complex formation. 
 
 Poly-D-L- lactide-co-glycolide (PLGA) 
Poly-D-L- lactide-co-glycolide (PLGA) is one of the most successfully used 
biodegradable polymers. It undergoes hydrolysis in the body to produce 
biodegradable metabolite monomers such as lactic acid and glycolic acid. Since 
lactic acid and glycolic acids are normally found in the body and participate in 
several physiological and biochemical pathways, there is very minimal systemic 
toxicity associated with the use of PLGA for the drug delivery or biomaterial 
applications. PLGA NPs have been mostly prepared by the emulsification-
diffusion, the solvent evaporation and the nanoprecipitation methods . PLGA 
nanoparticles have been used to develop protein and peptide based nanomedicines, 
nano-vaccines, and genes containing nanoparticles for in-vivo delivery systems. 
 Polylactic acid (PLA) 
PLA is a biocompatible and biodegradable polymer which is broken down 
to monomeric units of lactic acid in the body. Lactic acid is a natural 
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intermediate/by product of anaerobic respiration, which is converted into glucose 
by the liver during the Cori cycle. Glucose then is used as an energy source in the 
body. The use of PLA nanoparticles is therefore safe and devoid of any major 
toxicity. PLA nanoparticles have been mostly prepared by the solvent evaporation, 
solvent displacement, salting out and solvent diffusion methods. The salting out 
procedure is based on the separation of a water- miscible solvent from aqueous 
solution by adding a salting out agent like magnesium chloride or calcium chloride. 
The main advantage of the salting out procedure is that it minimizes stress to protein 
encapsulants. 
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CHITOSAN NANOPARTICLES 
Chitosan is a natural polymer obtained by deacetylation of chitin from 
crustacean shells such as crabs, shrimps and lobsters. After cellulose chitin is the 
second most abundant polysaccharide in nature. It is biologically safe, non-toxic, 
biocompatible and biodegradable polysaccharide. 
Figure 3: chitosan extraction 
   
 
Chitosan is a biodegradable, biocompatible, positively charged nontoxic 
Mucoadhesive biopolymer. Since chitosan contains primary amino groups in the 
main backbone that make the surfaces positively charged in biological fluids, 
biodegradable nano/microparticles can be readily prepared by treating chitosan with 
a variety of biocompatible polyanionic substances such as sulphate, citrate, and 
tripolyphosphate. 
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Chitosan nanoparticles have gained more attention as drug delivery carriers 
because of their better stability, low toxicity, simple and mild preparation method 
and providing versatile routes of administration. Chitosan has the special possibility 
of adhering to the mucosal surfaces with in the body because of their sub-micron 
size and is suitable for mucosal routes of administration i.e. oral, nasal and ocular 
mucosa which is non-invasive route. Chitosan nanoparticles showed to be a good 
adjuvant for vaccine also. 
Advantages of chitosan nanoparticles 
 Simple and inexpensive to manufacture and scale-up 
 No heat, high shear forces or organic solvents involved in their preparation 
 process 
 Reproducible and stable 
 Applicable to a broad category of drugs; small molecules, proteins and 
 polynucleotides 
 Ability to lyophilize 
 Stable after administration 
 Non-toxic 
 
PREPARATION METHODS OF CHITOSAN NANOPARTICLES 
Ionotropic gelation 
Chitosan NP prepared by ionotropic gelation technique was first reported by 
Calvo et al., (1997b) and has been widely examined and developed (Janes et al., 
2001; Pan et al., 2002). The mechanism of chitosan NP formation is based on 
electrostatic interaction between amine group of chitosan and negatively charge 
group of polyanion such as tripolyphosphate (Bodmeier et al., 1989; Xu and Du, 
2003). This technique offers a simple and mild preparation method in the aqueous 
environment. First, chitosan can be dissolved in acetic acid in the absence or 
presence of stabilizing agent, such as poloxamer, which can be added in the chitosan 
solution before or after the addition of polyanion. Polyanion or anionic polymers 
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was then added and nanoparticles were spontaneously formed under mechanical 
stirring at room temperature. The size and surface charge of particles can be 
modified by varying the ratio of chitosan and stabilizer. 
 
Micro emulsion method 
Chitosan NP prepared by micro emulsion technique was first developed by 
Maitra et al. This technique is based on formation of chitosan NP in the aqueous 
core of reverse micellar droplets and subsequently cross-linked through 
glutaraldehyde. In this method, a surfactant was dissolved in N-hexane. Then, 
chitosan in acetic solution and glutaraldehyde were added to surfactant/hexane 
mixture under continuous stirring at room temperature. Nanoparticles were formed 
in the presence of surfactant. The system was stirred overnight to complete the 
cross- linking process which the free amine group of chitosan conjugates with 
glutaraldehyde. The organic solvent is then removed by evaporation under low 
pressure. The yields obtained were the cross-linked chitosan NP and excess 
surfactant. The excess surfactant was then removed by precipitate with CaCl2 and 
then the precipitant was removed by centrifugation. The final nanoparticles 
suspension was dialyzed before lyophilisation. This technique offers a narrow size 
distribution of less than 100 nm and the particle size can be controlled by varying 
the amount of glutaraldehyde that alters the degree of cross-linking. Nevertheless, 
some disadvantages exist such as the use of organic solvent, time-consuming 
preparation process, and complexity in the washing step. 
 
Emulsification solvent diffusion method 
NP prepared by emulsion solvent diffusion method, (El-Shabouri, 2002) 
which originally developed by Niwa et al. employing PLGA. This method is based 
on the partial miscibility of an organic solvent with water. An o/w emulsion is 
obtained upon injection an organic phase into chitosan solution containing a 
stabilizing agent (i.e. poloxamer) under mechanical stirring, follow by high pressure 
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homogenization. The emulsion is then diluted with a large amount of water to 
overcome organic solvent miscibility in water. Polymer precipitation occurs 
because of the diffusion of organic solvent into water, leading to the formation of 
nanoparticles.  
 
Polyelectrolyte complex (PEC) 
Polyelectrolyte complex or self-assemble polyelectrolyte is a term to 
describe complexes formed by self-assembly of the cationic charged polymer and 
plasmid DNA. Mechanism of PEC formation involves charge neutralization 
between cationic polymer and DNA leading to a fall in hydrophilicity as the 
polyelectrolyte component self-assembly. Several cationic polymers (i.e. gelatin, 
polyethylenimine) also possess this property. Generally, this technique offers 
simple and mild preparation method without harsh conditions involved. The 
nanoparticles spontaneously formed after addition of DNA solution into chitosan 
dissolved in acetic acid solution, under mechanical stirring at or under room 
temperature (Erbacher et al., 1998). The complexes size can be varied from 50 nm 
to 700nm. 
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Figure 4: Ppreparation methods of chitosan nanoparticles 
 
 
Nasal drug delivery system 
In recent years, the nasal route has received a great deal of attention as a 
convenient and reliable method for the systemic administration of drugs.  However, 
polar drugs and some macromolecules are not absorbed in sufficient concentration 
due to poor membrane permeability, rapid clearance and enzymatic degradation 
into the nasal cavity. Earlier studies have demonstrated that intranasal 
administration offers a practical, non-invasive and an alternative route of 
administration for rapid drug delivery to brain. The large surface area of the nasal 
cavity and the relatively high blood flow, thereby achieving a rapid absorption and 
avoidance of hepatic first-pass elimination are attractive features of nasal drug 
administration. It also offers the advantages of being administered simply, cost 
effectively and conveniently. 
 
Diseases of the Central Nervous System (CNS) such as schizophrenia, 
meningitis, migraine, Parkinson’s disease and Alzheimer’s disease require delivery 
Formatted: Normal, Space After:  0 pt, Line spacing: 
single, Adjust space between Latin and Asian text, Adjust
space between Asian text and numbers
Introduction 
 
 
Department of  Pharmaceutics  24 
 
of the drug to the brain for treatment.  However, such transport remains problematic, 
especially for hydrophilic drugs and large molecular weight drugs, due to the 
impervious nature of the endothelial membrane separating the systemic circulation 
and central interstitial fluid, the Blood–Brain Barrier (BBB). Some of the currently 
employed invasive approaches (mechanically breaching the BBB) include   
interstitial delivery, intracerebroventricular delivery, intracerebral delivery, and 
convection enhanced delivery. It has been shown transport of exogenous materials 
directly from nose-to-brain is a potential route for by-passing the BBB. This route, 
involves the olfactory or trigeminal nerve systems which initiate in the brain and 
terminate in the nasal cavity at the olfactory neuroepithelium or respiratory 
epithelium, respectively. 
 
 
 
 
Advantages of Nasal Drug Delivery 
1)  Drug degradation that is observed in the gastrointestinal track is absent.  
2)  Hepatic first pass metabolism is avoided.  
3)   The nasal bioavailability for smaller drug molecule is good.  
4)  Studies so far indicates that the nasal route is an alternative to parenteral 
 route, especially for protein’s and peptide drug.  
5)   Convenient for the patient especially for those on long term therapy, when 
 compared with parenteral medication.  
6)   Polar compound exhibiting poor oral absorption may be particularly studies 
 for this route of delivery.  
7)   Large nasal mucosa surface area for dose absorption.  
8)  Ease of administration, non-invasive.  
9)  Lower dose reduced side effects.  
10)  Self-administration. 
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Limitations 
1) Delivery is expected to decrease with increasing molecular weight of drug.  
2) Mucosal damages may occur due to frequently use of intra nasal route. 
3) Difficult to administered drug in pathological condition such as nasal 
 congestion due to cold or allergic reaction.  
4) Some drug cannot have administered through this route because they cause 
 nasal irritation 
 
MIGRAINE 
Migraine is a syndrome that affects a significant fraction of the world 
population, with a higher prevalence in women (15%) than in men (6%). Migraine 
is characterized by an intense and throbbing headache associated with anorexia, 
nausea, vomiting, photophobia, phonophobia which is also accompanied by 
impairment of cognitive and motor functions. Migraine is more than “just a 
headache”. It is a complex neurological condition, which can affect the whole body 
and can result in many symptoms, sometimes without a headache at all. It can be 
easily overlooked or mistaken for other conditions and can affect people in different 
ways. Research is continuing, but at present we do not know what causes migraine; 
there is no clear diagnostic test and, yet, there is no cure. However, there are many 
ways to help manage the condition and lessen its impact – ultimately reducing the 
disruption caused to everyday life. 
 
Symptoms  
Symptoms of migraine can occur a while before the headache, immediately 
before the headache, during the headache and after the headache. Although not all 
migraines are the same, typical symptoms include: 
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 Moderate to severe pain, usually confined to one side of the head during an 
 attack, but t can occur on either side of the head 
 The pain is usually a severe, throbbing, pulsing pain 
 Increasing pain during physical activity 
 Inability to perform regular activities due to pain 
 Feeling sick and physically being sick 
 Increased sensitivity to light and sound, relieved by lying quietly in a 
 darkened room 
 Some people experience other symptoms such as sweating, temperature 
 changes, tummy ache, nausea or vomiting and diarrhoea. 
 Neurological symptoms that include visual disturbances such as blind spots, 
 distorted vision, flashing lights or zigzag patterns; 
 Other common aura symptoms you may experience include: tingling or pins 
and needles in the limbs, an inability to concentrate, confusion, difficulty in 
speaking, paralysis or loss of consciousness (in very rare cases). 
 
 
 
 
The five stages of an attack 
Although not all migraines follow the same pattern, there generally tend to 
be Five phases of a migraine attack: 
 
 The prodrome (warning) stage: Signs, such as mood changes, tiredness, an 
 unusual hunger or thirst can happen up to 48 hours before an attack. 
 The aura: This part of the attack can last up to an hour and usually precedes 
 the headache. Symptoms may include visual disturbances, pins and needles, 
confusion etc. 
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 The main stage of the attack: A headache will often be present along with 
other symptoms, such as nausea and / or vomiting and can last between 4 
and 72 hours. 
 Resolution / postdrome stage: The pain gradually eases or may disappear, 
 but feelings of lethargy or being ‘washed-out’ may remain. 
 Recovery stage: It can take a few days to fully recover, or for the more lucky 
 ones, recovery can be surprisingly quick. 
 
Common migraine ‘triggers’ 
 Stress 
 Lack of food or infrequent meals 
 Certain foods including products of caffeine, tyramine, alcohol, 
 monosodium glutamate 
 Changing sleep patterns 
 Hormonal patterns e.g. monthly periods, contraceptive pills. 
 Extreme emotions e.g. anger, or grief 
 Environmental factors e.g. loud noise, bright, flickering lights, strong 
 smells, hot stuffy atmospheres 
 Climatic conditions e.g. strong winds, extreme heat or cold.  
 
 
Figure : 5: Migraine Triggers 
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Pathophysiology of migraine 
Pathogenesis of migraine involves not only the intra and extra-cranial 
vasodilation but also activation of pain receptors of trigeminovascular system.  
In many cases, migraine attacks are likely to begin centrally, in brain areas 
capable of generating the classical neurological symptoms of prodromes and aura, 
whereas the headache phase begins with consequential activation of meningeal 
nociceptors at the origin of the trigeminovascular system (Noseda and Burstein, 
2013). While some clues about how the occurrence of aura can activate nociceptors 
in the meninges exist, nothing is known about the mechanisms by which common 
prodromes initiate the headache phase or what sequence of events they trigger that 
results in activation of the meningeal nociceptors. A mechanistic search for a 
common denominator in migraine symptomatology and characteristics points 
heavily toward a genetic predisposition to generalized neuronal hyperexcitability 
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(Ferrari et al., 2015). Mounting evidence for alterations in brain structure and 
function that are secondary to the repetitive state of headache can explain the 
progression of disease (Sprenger and Borsook, 2012). 
 
The complexity of pathophysiological mechanisms involved in migraine 
impedes its treatment, although a range of drugs with diverse pharmacological 
activities have evolved for its therapeutic management. 
 
The 5HT1B receptor located in large numbers on smooth muscle of 
meningeal blood vessels that mediates vasoconstriction; they are ideally placed to 
reverse the meningeal vasodilation that occurs during migraine attack. Triptans are 
warranted, because triptans are selective 5HT1B/1D agonists; and most effective in 
aborting headache when used early in pain phase. 
 
 
 
 
Migraine treatments 
Initially, migraine-specific management was based on the vascular model of 
headache advanced by Wolff and Graham after their seminal article in 1938 linking 
migraine to vasoconstriction; thus, vasoconstriction agents were sought that could 
terminate an attack. As a result, ergot preparations were developed and were 
efficacious, but with significant side effects. The 1990s saw a major advance with 
the introduction of Sumatriptan. This serotonin receptor 5-hydroxytryptamine 1 (5-
HT1) agonist was as effective as ergots but generally produced fewer concerning 
side effects. Presently, there are seven triptans. Their exact mechanism of action in 
migraine is unclear. They may inhibit neurogenic inflammation peripherally, inhibit 
nociceptive inputs to the central pain system, or act as peripheral vasoconstrictors. 
Further migraine-specific agents are in development. 
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Table 1: Drugs for treatment of migraine 
Drug Dose Half lifeHalf-life in hours 
Maximum daily 
dose 
Group 1: Fast Onset Triptans 
Almotriptan 6.25mg and 12.5 mg 3-4 hours 25 mg 
Elitriptan 20 mg and 40 mg 4 hours 80mg 
Rizatriptan 5mg and 10 mg 2-3 hours 30mg 
Sumatriptan 
25mg, 50 mg and 
100mg- orally 
3 hours 
200mg-  oral 
5mg and 20mg – intra 
nasal 
40mg – intra nasal 
6mg/0.5ml - 
subcutaneous 
12mg - 
subcutaneous 
Zolmitriptan 2.5mg and 5mg 3 hours 10mg 
Group 2:  slower onset triptans 
Frovatriptan 2.5mg tablet 26 7.5 
Naratriptan 1mg and 2.5 mg 6 5 
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RESEARCH OBJECTIVE 
 The rationale of this study is to design and evaluate the characteristics of 
Intra nasal delivery of chitosan nanoparticles containing almotriptan malate to 
treat migraine. In the present research work an attempt was made to develop a 
novel dosage form of intranasal brain targeted nanoparticles of almotriptan malate 
by using a biodegradable polymer chitosan using ionic gelation technique. 
 Almotriptan malate was selected as a model drug because of the following 
reasons: 
 It is used in treatment of migraine 
 It is having better water soluble property 
 It is having a shorter biological half-life of   4 hours 
OBJECTIVE OF THE STUDY  
 To synchronise  nasal drug delivery for enhanced activity 
 To enhance brain targeting of hydrophilic drug 
 To reduce the dose of drug. 
 To reduce dose dependent side effect. 
 To develop a sustained release formulation. 
 To overcome drug resistance. 
 
Plan of Research Work 
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PLAN OF RESEARCH WORK 
 Literature survey on almotriptan malate, nanoparticles, chitosan 
 nanoparticles, migraine 
 Selection of polymers 
 Preformulation studies 
 Preparation of chitosan nanoparticles loaded with almotriptan malate 
 Stastical optimisation 
 Characterisation studies and invitro drug release studies 
 Stability studies 
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LITERATURE REVIEW 
1. Girotra P et al., (2016) developed Poly (D, L Lactide-co-Glycolide) 
poloxamer nanoparticles (NPs) of the hydrophilic drug Zolmitriptan using 
quality-by-design approach for brain targeting. Randomized 24 full 
factorial design was employed to achieve the critical quality attributes of 
minimized particle size and maximized encapsulation efficiency. The 
PLGA/poloxamer NPs were fabricated using modified double emulsion 
solvent diffusion technique. The optimized nanoparticles were 
characterized by FTIR spectroscopy and powder X-ray diffraction 
technique which indicated the loading of drug in NPs without any 
chemical interactions between drug and the excipients. The uniform and 
spherical shape of the particles was affirmed from TEM analysis. The in-
vivo studies for determination of brain uptake potential demonstrated the 
pharmacodynamic studies involving Swiss albino mice further confirmed 
successful delivery of drug to brain circumventing the blood brain barrier, 
through significantly enhanced anti-migraine potential. 
 
2. Girotra P et al., (2016) developed a brain-targeted rizatriptan benzoate-
loaded solid lipid nanoparticles (RB-SLNs) by design of experiment, for 
improvement of its anti-migraine potential. Several formulation variables 
affecting the fabrication of RB-SLNs were screened using the Plackett-
Burman design (PBD). The PBD results demonstrated lipid (Precirol® 
ATO 5) concentration, co-surfactant (Phospholipon® 90 H) concentration 
and temperature of lipid melt to be the critical variables, having a 
significant effect on the achievement of minimum particle size, maximum 
entrapment efficiency coupled with sustained drug release. The optimized 
formulation was, thereafter, characterized by FTIR spectroscopy, wide 
angle XRD, thermal analysis and TEM imaging technique. The in vivo 
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studies revealed the brain uptake potential of optimized RB-SLNs to be 
18.43-folds higher the significant anti-migraine efficacy of RB-SLNs was 
corroborated through the pharmacodynamic studies on adult male Swiss 
albino mice. The results hence explicate that RB-SLNs have distinctly 
improved brain target ability and offer an apt approach for the efficient 
therapeutic management of migraine 
 
3. Sirisha Yella et al., (2016)., prepared and determined the effect of various 
diluents and super disintegrants in various ratios on drug release of 
Almotriptan. Orally disintegrating tablets of almotriptan have been 
developed to increase the bioavailability of the drug using optimization 
technique and effect of various excipients have been studied to obtain an 
optimized formulation. Diluents, microcrystalline cellulose, spray dried 
lactose, mannitol and starch were employed and superdisintegrants, cross 
povidone, cross carmellose sodium & sodium starch glycolate were used 
in different ratios. All the tablets were evaluated for precompression and 
post compression parameters. All the precompression parameters were 
found to be satisfactory. Among all the formulations F23having mannitol 
as diluent & SSG (8%) as superdisintegrant has shown maximum drug 
release of 100.03% within 20min whereas the marketed formulation shows 
release of 89.97%. The drug release from the optimised formulation 
followed first order kinetics. 
 
4. Sunena et al., (2016) formulated thiolated chitosan nanoparticles of 
zolmitriptan for brain targeting intranasal drug delivery. The thiolated 
chitosan was synthesized by reaction of thiogycolic acid and chitosan in 
presence of catalyst. The thiolated chitosan was characterized using FTIR 
and thermal studies. Drug loaded nanoparticles were prepared by ionic 
gelation of thiolated chitosan by using sodium tripolyphosphate. The 
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prepared nanoparticles were characterized by FTIR spectroscopy to 
confirm the drug loading without any chemical interactions between the 
drug and excipients. The morphology and size of the nanoparticles were 
affirmed by using TEM analysis. The drug permeation of nanoparticles 
through nasal mucosa was evaluated by Franz diffusion cell for intranasal 
drug delivery. 
 
5. Girotra Priti Hansraj et al., (2015) developed chitosan solid lipid 
nanoparticles (SLN), containing sumatriptan succinate using solvent 
injection method and to optimize the formulations for brain targeting 
potential. The formulation optimization was performed using three factor 
two level full factorial design the particle size, zeta potential and 
entrapment efficiency for all the batches were in the range of 192–301.4 
nm, 30.2–51.4 mV and 76.3–91.1% respectively. The optimized 
formulation showed a 4.54-fold increase in brain/blood ratio of drug after 
2 h of drug administration in male Wistar rats. The optimized 
nanoparticles were characterized by FT-IR spectroscopy, DSC, TGA, 
powder X-ray diffraction study and TEM analysis. The optimized 
formulated SLN exhibited sustained in vitro drug release by anomalous 
transport mechanism. 
 
6. Hansraj GP et al., (2015) prepared chitosan solid lipid nanoparticles 
(SLN), containing sumatriptan succinate using solvent injection method 
and optimized the formulations for brain targeting potential. The 
formulation optimization was performed using three factor two level full 
factorial design. It minimizes the particle size and zeta potential, maximize 
the entrapment efficiency as well as maximize the concentration of drug in 
brain with maximized brain/plasma ratio of the drug. The optimized 
nanoparticles were characterized by FT-IR spectroscopy, DSC, TGA, 
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powder X-ray diffraction study and TEM analysis.   The hydrophilic drug 
sumatriptan succinate, loaded in chitosan SLN, can be successfully 
targeted to brain via oral delivery and thus present an effective approach 
for the therapeutic management of migraine. 
 
7. Bhanushali et al., (2014) developed intranasal Nano emulsion and gel 
formulations for rizatriptan benzoate for prolonged action. Nano emulsion 
formulations were prepared by constructing pseudo-ternary phase 
diagrams using lipophilic and hydrophilic surfactants and water. Various 
Mucoadhesive agents were tried out to form thermo-triggered 
Mucoadhesive Nano emulsions. Mucoadhesive gel formulations of 
rizatriptan were prepared using different ratios of HPMC and Carbopol 
980. Comparative evaluation of intranasal Nano emulsions and intranasal 
Mucoadhesive gels indicated that greater brain-targeting could be achieved 
with Nano emulsions. 
 
8. Patil Satish K et al., (2014) developed a new type of solid lipid 
nanoparticles (SLN) of naratriptan by incorporating tripalmitine containing 
oils in the solid core of said particle. The hot high pressure 
homogenization technique was used as production methods for SLNs. 
Naratriptan is provide nose-to-brain delivery for brain targeting and 
sustained release. The drug-excipient study was performed by DSC and 
FTIR. The Solid Lipid Nanoparticles was evaluated and optimized for 
various parameters such as particle size, polydispersity index, zeta 
potential, encapsulation efficiency, in vitro drug release and stability 
studies were found to be110±1.4nm, 0.22±0.02, –16.21±4.02, 95.20±0.1 
and 98 % drug release respectively. SLNs formulation was subjected to 
stability study over a period of 3 month 
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9. Karva G. S et al., (2013) developed a quantitative estimation of 
Almotriptan Malate in pharmaceutical formulation. The stock solution of 
Almotriptan Malate was prepared and subsequent suitable dilution was 
prepared in 0.1N HCl to obtained standard curve. The standard solution of 
Almotriptan Malate showed two absorption maxima, one at 283.000 nm 
and another at 283.00 nm. The drug obeyed beer lambert’s law in the 
concentration range of 10-100 µg/ mL with regression 0.9998 at 283.00 
nm. The results of analysis have been validated as per ICH guidelines. The 
developed method can be adopted in routine analysis of Almotriptan 
Malate in tablet dosage form as well bulk dosage form. 
 
10. Narayana Charyulu R et al., (2013) designed and evaluate melt in mouth 
films of almotriptan using polymers pullulan, carragennan, xanthan gum 
and guar gum as the film forming agents. Glycerol was incorporated as 
plasticizer to improve flexibility of films, Sorbitol as sweetener and 
Sodium starch glycolate as disintegrant. This preparation melt in mouth 
films of almotriptan with the purpose of developing a dosage form for 
quick onset of action, which will be beneficial in managing severe 
condition of migraine attack, aiding in enhancement of bioavailability and 
easy for administration. The films were prepared by solvent casting 
method. They were evaluated for physicochemical characterization such as 
uniformity of weight, thickness, folding endurance, uniformity of drug 
content, surface pH, percentage elongation and tensile strength all of 
which showed satisfactory results. The formulations were also subjected 
for in vitro disintegration and in vitro drug release. 
 
11. Neha Gulati et al., (2013) developed and evaluated sumatriptan succinate-
loaded chitosan nanoparticles for. Sumatriptan succinate-loaded chitosan 
nanoparticles were successfully formulated via the ionotropic gelation 
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technique using the Taguchi design for optimization. The obtained 
nanoparticles easily penetrate the nasal mucosa by particle size. The 
formulation displayed sustained release up to 24 hours which may help to 
reduce multiple daily doses to once per day. 
 
12. Sagar S. Jadhav and Aparna V. Bhalerao., (2013) formulated and 
evaluated intranasal Mucoadhesive nanoparticles of Rizatriptan benzoate 
(RZB) for treatment of Migraine. RZB loaded Chitosan (CS) nanoparticles 
were prepared by ionic gelation of CS with tripolyphosphate anions (TPP). 
The maximum entrapment efficiency and drug content was 69.1% and 
60.63%, shown by optimized formulation. Particle size of optimized 
formulation was 0.248 μ shown by Zetasizer. Spray drying of optimized 
formulation was carried out and process yield was determined, which was 
found to be 38.78%. Spray dried nanoparticles were evaluated by DSC, X-
ray diffraction pattern to study crystalline/amorphous nature of 
nanoparticles. The percentage mucoadhesion on nasal mucosa of goat was 
found to be 29.4%. The release behaviour of CS nanoparticles were 
evaluated in phosphate buffer pH 6.5, revealed that RZB loaded CS 
nanoparticles is most suitable for intranasal drug delivery. 
 
13. Saugat Adhikari et al., (2012) formulated chitosan biodegradable 
nanoparticles of zolmitriptan for migraine treatment by the ionic gelation 
method using polyanion sodium tripolyphosphate (STPP) as a cross-
linking agent and their in-vitro characteristics were studied. Solid state 
analysis was undertaken using thermal methods (DSC/MDSC). The 
particle size and morphology was determined by laser scattering technique 
and transmission electron microscopy, respectively. FTIR and DSC 
showed no significant interactions between chitosan and drug, STPP and 
drug. The prepared nanoparticle shows maximum entrapment efficiency 
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with narrow particle size range. In dissolution testing zolmitriptan chitosan 
nanoparticle showed immediate release of ZMT followed by sustained 
release.  
 
14. Akhila Alladi et al., (2012) formulated and evaluated taste masked 
Almotriptan orally disintegrating tablet by using different taste masking 
agents and different superdisintegrants in different ratios. Two taste 
masking agents namely Eudragit EPO and Precirol A To5 are used to taste 
mask the drug. The oral disintegrating tablets of Almotriptan were 
prepared using different superdisintegrants and the effect of different 
superdisintegrants at different concentration on in-vitro release was 
studied. Almotriptan release from ODT was directly proportional to the 
concentration of the superdisintegrant used. The optimized formulation 
was found to release the drug in minimum time and is found to be stable. 
 
15. Bhavna, V. Sharma et al., (2007) prepared and characterised chitosan 
nanoparticles for nose to brain delivery of a cholinesterase inhibitor. he 
cholinesterase inhibitor chitosan nanoparticles were prepared by ion 
gelation method and characterized for the particle size, morphology and 
particle size distribution. The chitosan nanoparticles had a particle 
diameter ranging from 100-200 nm and the shape was spherical the 
nanoparticles showed a loading efficiency up to 92% and a loading 
capacity up to 50% (w/w). The Mucoadhesive property of chitosan and 
ability of Tween 80 to cross BBB will provide effective delivery of 
cholinesterase inhibitors from nose-to-brain to cross BBB. Thus, chitosan 
nanoparticles possess a potential to deliver cholinesterase inhibitor through 
the nasal mucosa to reach the brain for the treatment of neurodegenerative 
disease. 
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DRUG PROFILE 
ALMOTRIPTAN MALATE 
Chemical formula  
C21H31N3O7S 
Chemical name 
1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine. 
Chemical structure 
 
 
Physical state 
White to slightly yellow crystalline powder 
Solubility 
Freely soluble in water 
Molecular weight 
469.553 g/mol 
 
Drug Profile 
 
 
 
Department of  Pharmaceutics  39 
Drug category 
Selective serotonin receptor agonists 
Dosage forms 
6 and 12.5mg oral tablets 
Mechanism of action 
Almotriptan binds with high affinity to 5-HT1D, 5-HT1B, and 5-HT1F 
receptors. Almotriptan has weak affinity for 5-HT1A and 5-HT7 receptors, but 
has no significant affinity or pharmacological activity at 5-HT2, 5-HT3, 5-HT4, 5-
HT6; alpha or beta adrenergic; adenosine (A1, A2); angiotensin (AT1, AT2); 
dopamine (D1, D2); endothelin (ETA, ETB); or tachykinin (NK1, NK2, NK3) 
binding sites. 
Current theories on the etiology of migraine headache suggest that 
symptoms are due to local cranial vasodilatation and/or to the release of 
vasoactive and pro-inflammatory peptides from sensory nerve endings in an 
activated trigeminal system. The therapeutic activity of almotriptan in migraine 
can most likely be attributed to agonist effects at 5-HT1B/1D receptors on the 
extra cerebral, intracranial blood vessels that become dilated during a migraine 
attack, and on nerve terminals in the trigeminal system. Activation of these 
receptors results in cranial vessel constriction, inhibition of neuropeptide release, 
and reduced transmission in trigeminal pain pathways. 
Pharmacokinetic data 
Absorption 
The compound has a half-life of approximately 3 hours. Almotriptan is 
well absorbed after oral administration and the mean absolute bioavailability is 
69.1%. Maximal plasma concentrations are achieved between 1.5 and 4 hours 
after dose administration; however, within 1 hour after administration, plasma 
concentrations are approximately 68% of the value at 3 hours after administration. 
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Distribution and protein binding 
Almotriptan is not highly bound to plasma proteins and the mean unbound 
fraction is >60%. Therefore, plasma protein binding is not a major factor affecting 
the pharmacokinetics of almotriptan. The mean apparent volume of distribution is 
approximately 180 to 200 litres. The large volume of distribution and low degree 
of plasma protein binding are properties. 
Metabolism  
Almotriptan is metabolized by one minor and two major pathways. 
Monoamine oxidase (MAO)-mediated oxidative deamination (approximately  
27% of the dose), and cytochrome P450-mediated oxidation (approximately 12% 
of the dose) are the major routes of metabolism, while flavin monooxygenase is 
the minor route. MAO-A is responsible for the formation of the indoleacetic acid 
metabolite, whereas cytochrome P450 (3A4 and 2D6) catalyses the hydroxylation 
of the pyrrolidine ring to an intermediate that is further oxidized by aldehyde 
dehydrogenase to the gamma-aminobutyric acid derivative. Both metabolites are 
inactive. 
Excretion 
Approximately 40% of an administered dose is excreted unchanged in 
urine. Renal clearance exceeds the glomerular filtration rate by approximately  
3-fold, indicating an active mechanism. Approximately 13% of the administered 
dose is excreted via faeces, both unchanged and metabolized. 
Half life 
3-4 hours 
Contra indication 
Almotriptan should not be given to patients with ischemic heart disease or to 
patients who have symptoms or findings consistent with ischemic heart disease, 
coronary artery vasospasm, including Prinzmetal's variant angina or other 
significant underlying cardiovascular disease because 
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 It may increase blood pressure, it should not be given to patients with 
 uncontrolled hypertension 
 It should not be administered within 24 hours of treatment with another 5-
HT1 agonist, or an ergotamine-containing or ergot-type medication like 
dihydroergotamine or methysergide. 
 It is contraindicated in patients who are hypersensitive to almotriptan or 
any of its ingredients. 
 
Adverse effects 
Serious cardiac events, including myocardial infarction and coronary 
artery vasospasm, have occurred following the use of almotriptan malate. These 
events are extremely rare and most have been reported in patients with risk factors 
predictive of CAD. Events reported in association with drugs in this class have 
included coronary artery vasospasm, transient myocardial ischemia, myocardial 
infarction, ventricular tachycardia, and ventricular fibrillation. 
 
Side effects 
Almotriptan is generally well tolerated. The side effects are usually mild 
and do not last long. The following is not a complete list of side effects.  
The most common side effects are 
 Nausea 
 Sleepiness 
 Tingling or burning feeling (paraesthesia) 
 Headache 
 Dry mouth. 
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Drug interactions 
 Ergot-Containing Drugs 
These drugs have been reported to cause prolonged vasospastic reactions. 
Because there is a theoretical basis that these effects may be additive, use of 
ergotamine-containing or ergot-type medications (like dihydroergotamine or 
methysergide) and almotriptan within 24 hours of each other should be avoided. 
 
 Monoamine Oxidase Inhibitors 
Co-administration of moclobemide resulted in a 27% decrease in 
almotriptan clearance and an increase in Cmax of approximately 6%.  
 Other 5-HT1B/1D Agonists 
Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment 
with almotriptan is contraindicated. 
 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine 
Reuptake Inhibitors and Serotonin Syndrome 
Cases of life-threatening serotonin syndrome have been reported during 
combined use of selective serotonin reuptake inhibitors (SSRIs) or serotonin 
norepinephrine reuptake inhibitors (SNRIs) and triptans. 
 Verapamil 
Co-administration of almotriptan and verapamil resulted in a 24% increase 
in plasma concentrations of almotriptan.  
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POLYMER PROFILE 
CHITOSAN (Pankaj Shard1et.al, 2014) 
Non-proprietary names: 
BP: Chitosan hydrochloride 
PhEur: Chitosani hydrochloridum 
Synonyms: 
2-Amino-2-deoxy-(1,4)-β-D-glucopyranan; deacetylated chitin; 
deacetylchitin; β-1,4-poly-D-glucosamine; poly-D-glucosamine; poly-(1,4-β-D-
glucopyranosamine). 
Chemical name and CAS registry number: 
Poly-β-(1,4)-2-Amino-2-deoxy-D-glucose [9012-76=4] 
Functional category: 
 Coating agent 
 disintegrant 
 film-forming agent 
  tablet binder 
 Viscosity-increasing agent. 
Structural formula 
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Applications in pharmaceutical formulation: 
Chitosan is used in cosmetics and is under investigation for use in a 
number of pharmaceutical formulations. The suitability and performance of 
chitosan as a component of pharmaceutical formulations for drug delivery 
applications has been investigated innumerous studies. These include controlled 
drug delivery applications, use as a component of Mucoadhesive dosage forms, 
rapid release dosage forms, improved peptide delivery, colonic drug delivery 
systems, and use for gene delivery. Chitosan has been processed into several 
pharmaceutical forms including gels, films, beads, microspheres, tablets, and 
coatings for liposomes. Furthermore, chitosan may be processed into drug 
delivery systems using several techniques including spray-drying, coacervation, 
direct compression, and conventional granulation processes. 
Description: 
Chitosan occurs as odourless, white or creamy-white powder or flakes. 
Fibre formation is quite common during precipitation and the chitosan may look 
'cotton like'. 
Acidity/alkalinity:  
pH = 4.0–6.0 (1% w/v aqueous solution) 
Density:  
1.35–1.40 g/cm 
Solubility: 
It is sparingly soluble in water; practically insoluble in ethanol (95%), 
other organic solvents, and neutral or alkali solutions at pH above approximately 
6.5. Chitosan dissolves readily in dilute and concentrated solutions of most 
organic acids and to some extent in mineral inorganic acids (except phosphoric 
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and sulphuric acids). Upon dissolution, amine groups of the polymer become 
protonated, resulting in a positively charged polysaccharide and chitosan salts 
(chloride, glutamate, etc.) that are soluble in water; the solubility is affected by the 
degree of deacetylation. Solubility is also greatly influenced by the addition of salt 
to the solution. The higher the ionic strength, the lower the solubility as a result of 
a salting-out effect, which leads to the precipitation of chitosan in solution. When 
chitosan is in solution, the repulsions between the deacetylated units and their 
neighbouring glucosamine units cause it to exist in an extended conformation. 
Addition of an electrolyte reduces this effect and the molecule possesses a more 
random, coil-like conformation. 
Typical properties  
Chitosan is a cationic polyamine with a high charge density at pH <6.5; 
and so adheres to negatively charged surfaces and chelates metal ions. It is a linear 
polyelectrolyte with reactive hydroxyl and amino groups (available for chemical 
reaction and salt formation). The properties of chitosan relate to its polyelectrolyte 
and polymeric carbohydrate character. The presence of a number of amino groups 
allows chitosan to react chemically with anionic systems, which results in 
alteration of physicochemical characteristics of such combinations. The nitrogen 
in chitosan is mostly in the form of primary aliphatic amino groups. Chitosan 
therefore undergoes reactions typical of amines: for example, N acylation and 
Schiff reactions. Almost all functional properties of chitosan depend on the chain 
length, charge density, and charge distribution. Numerous studies have 
demonstrated that the salt form, molecular weight, and degree of deacetylation as 
well as pH at which the chitosan is used all influence how this polymer is utilized 
in pharmaceutical applications. 
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Stability and storage conditions 
Chitosan powder is a stable material at room temperature, although it is 
hygroscopic after drying. Chitosan should be stored in a tightly closed container in 
a cool, dry place. 
Incompatibilities 
Chitosan is incompatible with strong oxidizing agents. 
Safety 
Chitosan is being investigated widely for use as an excipient in oral and 
other pharmaceutical formulations. It is also used in cosmetics. Chitosan is 
generally regarded as a nontoxic and non-irritant material. It is biocompatible with 
both healthy and infected skin. Chitosan has been shown to be biodegradable. 
LD50 (mouse, oral) : >16 g/kg 
Regulatory Status 
Chitosan is registered as a food supplement in some countries. 
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SODIUM TRIPOLYPHOSPHATE 
Non-proprietary names 
BP: Sodium tripolyphosphate 
Synonyms:
 STP;s400;poly;STPP;armofos;polygon;tripoly;thermphos;thermphosn;rho
diaphoslv 
Chemical Name and CAS No. 
 Sodium tripolyphosphate (7758-29-4) 
Molecular Formula:  
Na5O10P3 
Molecular Weight:  
367.86 
Molecular structure 
 
Functional category 
Modifier; emulsifier; buffer; chelating agent; stabilizer. Can also be used 
as soft water, pH regulator and thickening agent. 
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Description 
Sodium tripolyphosphate is a colourless salt, which exists both in 
anhydrous form and as the hexahydrate. 
Application in pharmaceutical formulation or technology 
Sodium Tripolyphosphate is widely used as Dispersant in Pharmaceutical. 
It is used as a crosslinking agent.it is also used as a preservative and emulsifying 
agent. 
Materials & Equipments 
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MATERIALS AND EQUIPMENTS 
Materials Used 
Material Source 
Almotriptan Malate Azakem Laboratories , Hyderabad 
Chitosan Sigma Aldrich, Mumbai 
Sodium Tripoly Phosphate Sigma Aldrich, Mumbai 
Glacial Acetic Acid Sigma Aldrich, Mumbai 
 
Equipments Used 
Equipments Model/ Company 
pH Tester Eutech Instruments 
Magnetic Stirrer REMI – 2MLH 
Laboratory Centrifuge REMI 
Transmission Electron Microscopy CUSAT, Cochin 
UV – Visible Spectrophotometer Jasco v 530 
Dissolution Apparatus Electro lb TDT 08L 
FT-IR Spectrophotometer Jasco FTIR 4100 
Differential Scanning Calorimeter CUSAT, Cochin 
Thermoanalyzer CUSAT, Cochin 
Diffractometer CUSAT, Cochin 
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EXPERIMENTAL METHODS 
 
I. PREFORMULATION STUDIES 
Solubility studies 
Weighed accurately 10mg of the drug. Dissolved it in 5ml of the following 
solutions 
i. Water 
ii. Glacial acetic acid 
iii. Phosphate buffer 
 
Preparation of Calibration curve of almotriptan malate 
Preparation of pH 6.5 phosphate buffer (IP 2007 vol 1) 
Dissolved 60.5g of disodium hydrogen phosphate and 46g of potassium 
dihydrogen phosphate in water, add 100ml of 0.02m disodium edetate was added 
and 20 mg of mercuric Chloride was diluted with water to produce 1000ml. 
 
Calibration curve of almotriptan malate 
100mg of almotriptan malate was accurately weighed into 100ml 
volumetric flask and dissolved in methanol. The volume was made upto ml with 
6.5 phosphate buffer solution to get a concentration of 1000µg/ml from this, 10ml 
was withdrawn and diluted to 100ml with 6.5Ph phosphate buffer solution to get a 
concentrstion100µg/ml. From the standard stock solution 0.2ml, 0.4ml, 0.8ml and 
1ml were withdrawn and volume was made upto pH 6.5 phosphate buffer to give 
a concentration of 2,4,6,8, and 10 µg/ml. Absorbance of these solutions were 
measured against blank of pH 6.5 phosphate buffer solution at 227 nm. 
 
 
Experimental Methods 
 
 
Department of  Pharmaceutics  51 
FTIR studies (Sagar S.Jadhav et al., 2013) 
The FT-IR studies are conducted by potassium bromide disc pellet 
method. 10mg of the samples and 400mg of KBr were taken in a mortar and 
triturated. A small amount of the triturated sample was taken into the pellet maker. 
It was compressed at 10kgm/cm2 using a hydraulic press. The pellet was taken on 
the sample holder. It was then scanned from 4000cm-1 to 400cm-1 in FT IR 
spectrophotometer. Samples were prepared for drug and excipients also. The 
spectra obtained were compared and interrupted for functional group peaks 
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II. PREPARATION OF NANOPARTICLES (Saugat Adhikari  
 et. al.,2012) 
Chitosan biodegradable nanoparticles were prepared based on the ionic 
gelation of chitosan with sodium tripolyphosphate anions. Chitosan was dissolved 
in aqueous acetic solution at concentration (1%w/v). The concentration of acetic 
acid in aqueous solution was 1.5 times that of chitosan. Blank nanoparticles are 
obtained upon the addition of 4ml sodium tripolyphosphate aqueous solution with 
concentration of 0.5, 1.0, 1.5 mg/ml under magnetic stirrer at room temperature. 
Drug loaded nanoparticles were formed upon incorporation of 4ml sodium 
tripolyphosphate into 10ml chitosan solution with known concentration containing 
almotriptan. The nanoparticle suspension obtained was centrifuged at 10000 rpm 
for 30min, washed and dried 
Table 1 Formulation Of Chitosan Nanoparticle 
p Batch code Chitosan (mg/ml) 
Sodium 
Tripolyphosphate 
(mg/ml) 
Almotriptan 
Drug (mg) 
1 B0 1 0.5 0 
2 B1 1 0.5 2 
3 B2 2 1 2 
4 B3 3 1.5 2 
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III. STATISTICAL OPTIMIZATION USING 23 FACTORIAL 
DESIGN (Girotra PritiHansraj et al,. 2013) 
Preliminary experiments, performed to determine the major factors 
affecting the particle size and entrapment efficiency of the nanoparticles, 
suggested that the concentration of polymer chitosan, cross linking agent 
and surfactant tween 80, were the most significant factors. A 23 factorial 
design was selected to evaluate the effect of these three factors each at two 
levels, on       the dependent variables viz. particle size and entrapment 
efficiency. A total of four   experimental runs for the estimation of pure 
error were developed and the NPs were formulated. Details of the 
experimental design have been summarized in Table. The experimental 
design and all the regressions were performed using Minitab 17. 
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IV. CHARACTERIZATION OF NANOPARTICLE 
Morphological characterization and particle size determination of 
nanoparticles (Sagar S.Jadhav et al., 2013) 
 Particle morphology and particle size were examined by transmission 
electron microscopy (TEM). The samples were immobilized in the carbon/ 
formvar coated copper grids. They were dried at room temperature, and then were 
examined using a TEM without being stained. 
Determination of almotriptan loading capacity and entrapment efficiency 
(Sagar S.Jadhav et al., 2013) 
The entrapment efficiency can be determined by measuring the 
concentration of the free drug in the dispersion. Entrapment efficiency and drug 
loading capacity of nanoparticles in different formulation are determined by ultra-
centrifugation of samples at 10,000 rpm for 30 min. The amount of free 
almotriptan was determined in clear supernatant by UV spectrophotometry at 
227nm using supernatant of non-loaded (blank) nanoparticles as basic correction. 
The drug loading capacity of nanoparticles and entrapment efficiency (EE) of the 
process were calculated from equations 1 and 2 indicated below: 
 ܧ݊ݐݎ𝑎݌݉݁݊ݐ ܧ݂݂𝑖ܿ𝑖݁݊ܿ𝑦ሺܧܧ%ሻ= ݐ݋ݐ𝑎݈ 𝑎݉݋ݑ݊ݐ ݋݂ ݀ݎݑ݃ − ݂ݎ݁݁ ݀ݎݑ݃ݐ݋ݐ𝑎݈ ݀ݎݑ݃ × ͳͲͲ 
 ܦݎݑ݃ ݈݋𝑎݀𝑖݊݃ ܿ𝑎݌𝑎ܿ𝑖ݐ𝑦 = ݐ݋ݐ𝑎݈ 𝑎݉݋ݑ݊ݐ ݋݂ ݀ݎݑ݃ − ݂ݎ݁݁ ݀ݎݑ݃ݐ݋ݐ𝑎݈ 𝑤݁𝑖݃ℎݐ ݋݂ ݊𝑎݊݋݌𝑎ݎݐ𝑖݈ܿ݁ݏ × ͳͲͲ 
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Invitro drug release study of the prepared formulations (Sagar  S.Jadhav et al., 
2013) 
The in vitro drug release study of the optimized batch is to be performed in 
a USP Type II (Paddle type) apparatus using the principle of diffusion through the 
dialysis membrane. Drug loaded nanoparticles redispersed in 2 ml phosphate 
buffer (pH 6.5), were placed in a dialysis bag soaked in distilled water 1Hour prior 
to its use, and the bag was tied to the paddle of the apparatus. The paddle was 
rotated at 100 rpm and the dissolution media was 500 ml phosphate buffer pH 6.5 
maintained at 37 ◦C±1+C. Sample aliquots of 5 ml were collected at specific time 
intervals and were replenished with equal amount of fresh dissolution medium. 
The samples were analysed, spectrophotometrically at λmax = 227 nm against 
suitable blank and amount of drug released at various time intervals were 
calculated. The results were expressed in terms of average % drug release± 
standard deviation. 
In vitro drug release kinetics 
The drug release kinetics of almotriptan nanoparticles was determined by 
plotting the following kinetic models, using the data collected from in-vitro 
release studies. (zero order, first order and Higuchi equations). The mechanism of 
drug release was determined by using Korsmeyer-Peppas equations. 
 
a) Zero-Order Kinetics: 
Cumulative amount of drug released was plotted against time.  
C = K0T 
 where K0 is the zero-order rate constant expressed in units of 
concentration/time and t is the time in hours. A graph of concentration Vs time 
would yield a straight line with a slope equal to K0 and intercept the origin of the 
axis. This kinetics describes concentration independent drug release from the 
formulations. 
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b) First order kinetics:  
First order as log cumulative percentage of drug remaining vs time. This 
kinetics describes concentration dependent drug release from the formulations.   
Log C = Log Co-Kt / 2.303 
where C0 is the initial concentration of drug, k is the first order constant, and t is 
the time. 
c) Higuchi’s Model:  
Higuchi’s model as cumulative percentage of drug released vs. square root 
of time.  
Q = Kt1/2 
where K is the constant reflecting the design variables of the system and t is the 
time in hours. This model describes the release of drug on the basis of Fickian 
diffusion as a square root of time dependent process from swellable matrix. 
 
d) Korsmeyer-Peppas Equations:  
The mechanism of drug release, the first 60% of drug release were plotted 
in Korsmeyer equation log cumulative percentage of drug released vs log time, 
and the exponent n was calculated through the slope of the straight line,  
Mt / M∞ = Ktn 
 Where Mt/M∞ is the fractional solute release, t is the release time, K is a 
kinetic constant. Characteristic of the drug/polymer system, and n is an exponent 
that characterizes the mechanism of release of tracers. For cylindrical matrix 
tablets, if the exponent n = 0.45, then the drug release mechanism is Fickian 
diffusion, and if 0.45 <n < 0.89, then it is non-Fickian or anomalous diffusion. An 
exponent value of 0.89 is indicative of Case-II Transport or typical zero-order 
release (Balaiah. A et al.,2012). 
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Differential Scanning Calorimetry (DSC) (Sagar S.Jadhav et al., 2013) 
DSC thermograms of pure drug almotriptan malate, drug loaded optimized 
formulation and optimized formulation without drug were recorded on a DSC 
equipment to determine the physical nature of the drug and the polymers/carriers 
in the formulation. 4–5 mg of each of the samples were weighed in aluminium 
pans and then crimped. The samples were scanned in the temperature range of 25–
400 ◦C at a heat flow rate of 10 ◦C/min. The sample cell was continuously purged 
with nitrogen at a flow rate of 100 ml/min. The data is then analysed. 
 
 
Thermogravimetric analysis (TGA) (Sagar S.Jadhav et al., 2013) 
Thermoanalyzer was used for acquiring the thermo grams of drug 
almotriptan malate, Dummy nanoparticle and optimized formulation. The 
equipment was operated under nitrogen atmosphere, from 30◦ to 500 ◦C at a 
heating rate of 10 ◦C/min. The results were expressed in terms of per cent weight 
loss with respect to temperature. 
 
Powder X-ray diffraction study (Sagar S.Jadhav et al., 2013) 
The XRD patterns of pure drug, dummy nanoparticle and optimized 
nanoparticle are to be measured on a diffractometer. Monochromatic radiation  
(λ = 1.5418A˚), at 40 kV and 40 mA, were used as the X-ray source. The 
diffractograms were recorded between 20º and 70º with an increasing step of 
 0.02º and 2 s as the time for each step. 
 
Mucoadhesive Test (Sagar S.Jadhav et al., 2013) 
A piece of goat nasal mucosa was cleaned and placed in Krebs solution in 
Petri plate. It was washed with distilled water, and then accurately weighed RZB 
loaded CS Nanoparticles equivalent to 100 mg were spread on to it. The mucosa 
was kept aside for 5 min. Then surface was washed with phosphate buffer pH 6.5. 
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Nanoparticles retained on mucosal surface after first washing were removed with 
rinsing thoroughly by phosphate buffer 6.5. The solution was stirred to dissolve 
drug, filtered and absorbance was recorded. The amount of adhered microspheres 
was estimated as the difference between the amount of applied microspheres and 
the amount of flowed microspheres. The percent mucoadhesion was calculated 
using the following  ݌݁ݎܿ݁݊ݐ𝑎݃݁ ݋݂ ݉ݑܿ݋𝑎݀ℎݏ݁ݏ𝑖݋݊= 𝑎݉݋ݑ݊ݐ ݋݂ ݀ݎݑ݃ 𝑖݊ 𝑤𝑎ݏℎ ݋ݑݐ ݈𝑖ݍݑ𝑖݀𝑎ܿݐݑ𝑎݈ 𝑎݉݋ݑ݊ݐ ݋݂ ݀ݎݑ݃ 𝑖݊ ݊𝑎݊݋݌𝑎ݎݐ𝑖݈ܿ݁ݏ × ͳͲͲ 
 
V. STABILITY STUDIES  
A study was also carried out to assess the stability of almotriptan malate 
loaded chitosan nanoparticles. For this purpose, samples were kept in borosilicate 
glass vials and stored at room temperature, in a refrigerator (5 ± 1°C), and  
45 ± 1°C (75% relative humidity) in the stability chamber. Samples were analysed 
at the intervals of 0, 7, 14, 21, 28, 35, and 45 days for their changes in physical 
appearance and for the drug content. 
 
Results & Discussion 
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RESULTS AND DISCUSSION 
I. PREFORMULATION STUDIES 
Solubility studies 
Solubility studies was carried out to select a suitable solvent to dissolve the 
drug and to select the dissolution medium. 
Table 2: Solubility Studies 
Sl. No Solvent Solubility 
1 Water Soluble 
2 Phosphate buffer pH 6.5 Soluble 
3 Glacial acetic acid Soluble 
 
Calibration curve of almotriptan malate 
In the validation studies, it was found that the estimation of almotriptan 
malate by spectrophotometric method at 227 has good reproducibility, at the 
concentration between 2-10µg/ml. correlation between concentration and 
absorbance was found to be 0.9997845 which is closer to 1. 
 
Table 3: Calibration curve of almotriptan 
Si No Concentration Absorbance At 227nm 
1 2 0.017 
2 4 0.036 
3 6 0.055 
4 8 0.072 
5 10 0.089 
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Graph 1: Calibration curve of almotriptan malate 
 
FTIR studies 
The compactability studies between the drug and polymers were evaluated 
by using IR matching approach. 
Graph 2: FTIR Of Almotriptan 
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Table 4: FTIR Interpterion Of Drug Almotriptan Malate 
FTIR INTERPETION OF DRUG ALMOTRPTAN MALATE 
Materials Function Group Type of Vibration 
Characteristic 
Absorptions 
(Cm-1) 
Test 
Absorption 
 
Almotriptan 
malate 
CH stretching 2840-3000 2976.59 
 bending 1350-1480 1433.82 
NH stretching 3400-3500 3429.78 
C=C  1400-1600 1433.82 
S=O  1030-1060 1038.45 
COOH 0H  2500-3300 2563.21 
C-O  1210-1320 1229.12 
 
Graph 3: FTIR of almotriptan and chitosan 
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Table 5: FTIR interpretation of almotriptan and chitosan 
 
II. PREPARATION OF ALMOTRIPTAN NANOPARTICLE 
3 formulation and a blank formulation of almotriptan malate loaded 
chitosan nanoparticles were prepared using ion gelation method by using sodium 
tripolyphosphate as cross linking agent.  
Figure 6 : Prepared Nanoparticles 
 
FTIR INTERPETION OF DRUG ALMOTRPTAN MALATE  
AND CHITOSAN 
Materials Function 
Group 
Type of 
Vibration 
Characteristic 
Absorptions 
(Cm-1) 
Test 
Absorption 
 
 
 
Chitosan 
OH Stretching 3200-3520 3336 
C-O-C Stretching 1850 -2150 1187.58 
NH2 Stretching 3300- 3500 3455 
CH Stretching 2850-2950 2943 
Results & Discussion 
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III. STATISTICAL OPTIMIZATION USING 23 FACTORIAL DESIGN 
Eight formulations were prepared in accordance with the design layout 
generated by 23 full factorial design. The influence of three formulation 
parameters viz. concentration of chitosan, concentration of STPP and amount of 
tween80 on the five response variables, viz. particle size and entrapment 
efficiency was investigated. The results of the responses have been presented in 
below figures. The mean particle size of all the formulation batches ranged 
between 100 - 234. The entrapment efficiency of the formulations varied between 
32% and 81%. 
The equations obtained by the regression analysis for the two response 
variables are as follows: ݌𝑎ݎݐ𝑐݈݁ ݏ𝑖ݖ݁ = ͳͻͲ.͸ + ͳͻ.ͻ𝑐ℎ𝑖ݐ݋ݏ𝑎݊ 𝑐݋݊𝑐݁݊ݐݎ𝑎ݐ𝑖݋݊− ͳͷ.͸ܵܶ𝑃𝑃 𝑐݋݊𝑐݁݊ݐݎ𝑎ݐ𝑖݋݊ + ʹͲ.ͳ ݐ𝑤݁݁݊ͺͲ 𝑐݋݊𝑐݁݊ݐݎ𝑎ݐ𝑖݋݊ 
               ݁݊ݐݎ𝑎݌݉݁݊ݐ ݂݂݁𝑖𝑐𝑖݁݊𝑐ݕ = ͷͺ.͹ͷ − ͸.͹ͷ𝑐ℎ𝑖ݐ݋ݏ𝑎݊ 𝑐݋݊𝑐݁݊ݐݎ𝑎ݐ𝑖݋݊ +͹.ʹͷ ܵܶ𝑃𝑃𝑐݋݊𝑐݁݊ݐݎ𝑎ݐ𝑖݋݊ − ͸.ͷͲ ݐ𝑤݁݁݊ ͺͲ 𝑐݋݊𝑐݁݊ݐݎ𝑎ݐ𝑖݋݊ 
The cube plots, highlighting the effect of three formulation factors on the 
two response variables, have been depicted in figure. The effect of chitosan 
concentration, STPP concentration and tween 80 concentration on the particle size 
of the formulation has been represented in Fig.7. It was observed that particle size 
increases with the increase in chitosan. The effect of chitosan concentration, STPP 
concentration and tween 80 concentration on the particle size of the formulation 
has been represented in Fig.8. Presence of chitosan was more prominent factor 
affecting entrapment efficiency which may be ascribed to rigidization of 
nanoparticle. 
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Figure 7: Cube Plot For Particle Size 
 
Figure 8: Cube Plot For entrapment efficiency 
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IV.CHARACTERIZATION OF NANOPARTICLES 
1. Morphological characterization and particle size determination of 
 nanoparticles 
Particle morphology and particle size were examined by transmission 
electron microscopy (TEM).  
The TEM image of drug loaded optimized chitosan nanoparticle, displayed 
below, reveals that the particles were  
 Segregated 
 Uniform in size  
 Spherical in shape. 
The nanoparticles were within a narrow size distribution range in B0, B1 
and B2 batches and particle size slightly increased in B3 batch with high 
concentration of each composition. 
Table 6: Particle size range 
Sl. No Batch code Size range (nm) 
1 B0 100nm 
2 B1 100nm 
3 B2 157nm 
4 B3 183nm 
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Figure 9: TEM Image Of B0 
 
B0 
SHAPE: SPHERICAL 
SIZE: 100NM 
 
Figure 10: TEM Image Of B2 
 
B1  
SHAPE – SPHERICAL 
SIZE -100nm 
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Figure 11: TEM Image of B2 
 
B2 SHAPE: SPHERICAL 
SIZE 159 NM 
Figure 12: TEM Image Of B3 
 
B3 
SHAPE: SPHERICAL 
SIZE :183NM 
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Determination of almotriptan loading capacity and entrapment efficiency 
Entrapment efficiency means that the amount of drug in the precipitate did 
not change via different formulations. But, for constant amount of entrapped drug, 
upon increasing surfactant concentration the number of excipients increases, 
which results in reduced drug loading. 
 
Table 7: Entrapment Efficiency And Drug Loading Capacity 
Si no Batch code Entrapment 
efficiency (EE%) 
Almotriptan Drug 
Loading Capacity 
1 B1 81.9% 16.38 
2 B2 77.35% 15.47 
3 B3 73.5% 14.79 
 
Graph 4: Entrapment Efficiency And Drug Loading Capacity 
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Percentage Entrapment efficiency was found to be highest for B1 
formulation which is 81.9% whereas the lowest entrapment of drug was found to 
be for B3 having 73.5%. 
Drug loading capacity was more for B1 and less for B3. 
 
Invitro drug release study of the prepared formulations 
 The in-vitro release profile of ZMT from different formulations is shown 
in figure the percent drug release was not same for all the formulations.it varies 
with time. 
 
The release profile for chitosan biodegradable nanoparticles was obtained 
in phosphate buffer solution, pH 6.5. Initially the chitosan nanoparticles showed 
immediate release of almotriptan malate, with about 60% ZMT being released in 
45 minutes which may be due to release of drug from the surface nanoparticles, 
followed by slow release of drug which is encapsulated in CBN. When the particle 
size of drug loaded chitosan, nanoparticles is smaller, surface area tends to 
become larger and hence the drug release is faster. 
 
Table 8: Cumulative percentage release studies 
Time (min) 
Cumulative percentage release 
Batch 1 Batch 2 Batch 3 
0 0 0 0 
5 37 32 28 
10 45 43 39 
15 54 51 48 
30 57 53 50 
45 66 60 58 
60 71 65 61 
75 75 71 66 
90 79 75 72 
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Graph 5: In vitro drug release studies 
 
 
Figure 13: Dialysis membrane 150 with nanoparticles 
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Invitro drug release kinetics of the optimized formulations 
To analyse the mechanism for the release and release rate kinetics of the 
dosage form, the data obtained from in-vitro drug release from optimised 
formulation were fitted to model’s representation zero order, first order, Higuchi 
and Korsemeyer-Peppas. The data indicates a lesser amount of linearity when 
plotted by the zero-order equation. Hence, it can be concluded that the major 
mechanism of drug release follows first order kinetics. Understanding the 
mechanism of drug release is possible by configuring the data into mathematical 
modelling of Korsmeyer-Peppas plots. Plotting of graph using percentage release 
vs. square root of time, revealed linearity. Data based on the first order models 
usually provide evidence to the diffusion mechanism of drug release from 
sustained release delivery systems. 
Kinetic studies of batch 1 (B1) 
Graph 6: Zero order kinetics of B1 
 
 
0
20
40
60
80
100
0 4 8 12 16 20 24
%
 o
f 
C
u
m
u
la
ti
v
e
 D
ru
g
 R
e
le
a
se
Time (h)
Zero order Release
Zero order Release
Results & Discussion 
 
 
 
Department of  Pharmaceutics  72 
Graph 7: First order kinetics of batch 1 
 
 
Graph 8: peppas model of batch 1 
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Graph 10: Higuchi model of batch 1 
 
2. Differential scanning calorimetry 
The DSC thermograms reveal the melting point and the crystalline or 
amorphous behaviour of the drug and the carriers.  
Graph 11: DSC Thermogram Of Drug Almotriptan 
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Thermal analysis indicated that the DSC scan of the drug presented a sharp 
endothermic peak. A sharp endothermic peak was obtained at 124.75°C in the 
thermogram of the pure drug almotriptan malate, indicating  
 its melting point temperature  
  crystalline state.  
Graph 12: DSC Thermogram Of Almotriptan Loaded Nanoparticles 
 
 
 The endothermic peaks at 64ºC in the thermogram of blank nanoparticles 
corresponded to the melting point of sodium tripolyphosphate, present in 
the formulation.  
 The melting point peaks of chitosan were not observed because of their 
amorphous nature. 
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Graph 13: DSC Thermogram Of Blank Nanoparticles 
 
 
DSC spectrum of Chitosan Nanoparticles loaded with drug almotriptan 
does not exhibit the sharp peak of almotriptan malate. Thus, we can have 
concluded that in the Chitosan nanoparticles of almotriptan malate, drug was in 
partial crystalline state in chitosan nanoparticles and there is no interaction 
between drug and polymer. 
 
Thermogravimetric analysis 
Result awaiting 
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Powder X-ray diffraction study 
XRD studies are useful to investigate the crystallinity of drug in the 
chitosan nanoparticles. The X-ray diffractograms recorded for pure Almotriptan 
malate, blank nanoparticles and drug-loaded nanoparticles are presented. ALM 
revealed characteristic intense peaks at 2θ of 16°, 17° and 22° which are due to 
crystalline nature of ALM. However, in case of blank nanoparticles and drug-
loaded chitosan nanoparticles no intense peaks were observed between 2θ of 16°, 
17° and 22° indicating amorphous nature of the drug substance after entrapment 
into chitosan nanoparticles. It can be concluded that, drug particles are dispersed 
at the molecular level in the polymer matrices since no indication about the 
crystalline nature of the drug was observed in the drug-loaded chitosan 
nanoparticles. 
Graph 14: Powder Diffraction Studies Of Drug, Drug Loaded NP, Blank NP 
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Mucoadhesive Test 
Mucoadhesion studies were performed to ensure the adhesion of 
formulation to the mucosa for a prolonged period at the site of absorption. The 
results of the mucoadhesion studies are shown in the below table. The results 
indicated that amount of chitosan and volume of sodium tripolyphosphate was 
directly proportional to mucoadhesion strength. This could be attributed to the 
availability of a high amount of polymer for interaction with mucus.  
Table 9: Percentage Mucoadhesion Of The Drug Loaded NP 
Sl. No Batch code 
Percentage mucoadhesion (%) 
Of the drug loaded NP 
1 B1 69 
2 B2 61 
3 B3 54 
  
Graph 14: Percentage Mucoadhesion Of The Drug Loaded NP 
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Fig 14: Nasal mucosa in kreb’s solution 
 
Fig 15: Nasal mucosa in phosphate buffer pH 6.5 
 
Fig 16: Nasal mucosa with drug loaded chitosan nanoparticles 
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V. STABILITY STUDIES 
The nanoparticles were taken and observed their physical properties at an 
interval 0f 7, 14,21,28,35 and 45 days. no change was observed in their physical 
appearance. Colour remains the same. The drug content remains unchanged in 5 ± 
1°C and room temperature. 
Table 11: Drug Content in Stability Studies 
Si.no Sampling interval days 
Drug content 
5 ± 1°C Room temperature 45 ± 2°C 
1 7 100 100 100 
2 14 99.5 99.5 99.5 
3 21 99.2 98.4 98.3 
4 28 99.1 97.4 86.5 
5 35 98.8 96.5 77.9 
6 45 98.1 94.3 74.3 
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SUMMARY AND CONCLUSION 
Nanoparticles are designed to improve the pharmacological and therapeutic 
properties of conventional drugs. Due to small dimensions, nanoparticles can cross 
the blood-brain barrier (BBB) and operate on cellular level. There is a wide range 
of nanoparticulate materials and structures being developed for the delivery of 
therapeutic compounds. Each has its own advantages, but as these nanoparticles 
become optimized for their specific application, the outcome will be better-
controlled therapy because of targeted delivery of smaller amounts of effective 
drugs to the required sites in the body. This is being made possible using advanced 
material, improved control of particle size, and better understanding of interface 
between the biological and material surfaces, and their effects in vivo.  
Almotriptan malate is an antimigraine drug. It exerts its pharmacological 
action by vasoconstriction of the meningeal arteries, inhibition of release of the 
neurotransmitters from neurons in brain, prevention of the nociceptive transmission 
and reduction of the activity of trigeminal nerves. 
So, the present work was aimed to develop a novel approach for nose to 
brain targeted chitosan nanoparticle loaded with almotriptan malate for the 
treatment of migraine. 
Chitosan biodegradable nanoparticles (CBN) of almotriptan malate were 
prepared by the ionic gelation method using polyanion sodium tripolyphosphate 
(STPP) as a cross-linking agent and their in-vitro characteristics were studied. The 
different formulations with varying concentration of chitosan and STPP was 
prepared. Solid state analysis was undertaken using thermal methods 
(DSC/MDSC), and Fourier transform infra-red spectroscopy (FT-IR) for 
compatibility studies. The particle size and morphology was determined by 
transmission electron microscopy. FTIR showed no significant interactions 
between chitosan and drug, STPP and drug.  
Summary & Conclusion 
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The present study demonstrated the optimization of almotriptan malate 
loaded chitosan nanoparticles, using 23 full factorial design so as to develop an 
effective strategy for the decreased particle size, increased entrapment efficiency 
with maximum brain targeting efficiency. Optimization aided in understanding the 
interaction of formulation parameters, which can be exemplified by increased 
particle size with decreased chitosan concentration. Chitosan led to the increase in 
entrapment efficiency and STPP as well as Tween 80, conjointly, assisted in drug 
deposition in brain, probably by surpassing the blood brain barrier owing to their 
lipophilic and surfactant properties 
Particle size distribution analysis confirmed the size ranges, with a narrow 
size distribution. TEM indicated smooth and spherical Nanoparticles.  
The drug was chemically stable, with 73%5 to 81.9% entrapment efficiency 
and 14.79% to 16.38% drug loading in the nanoparticles. The polymer 
concentration was found to influence the % entrapment efficiency and release 
characteristics of nanoparticles. 
The in-vitro drug release studies by using dialysis membrane 150 showed 
that after the initial burst, all the different drug-loaded CBN provided a continuous 
and slow release of the drug. The CBN system demonstrates capability to 
almotriptan, antimigraine drug to potentially provide an effective treatment option 
in migraine therapy. In-vitro kinetic studies was also performed and it indicates a 
lesser amount of linearity when plotted by the zero-order equation. Hence, it can be 
concluded that the major mechanism of drug release follows first order kinetics. 
Polymer and drug was found to be compatible from DSC studies and powder 
x-ray diffraction studies. Mucoadhesion studies were also conducted using goat 
nasal mucosa and mucoadhesion percentage was between 54% and 69%. It was 
concluded that mucoadhesive nanoparticles as intranasal formulation is an 
alternative drug delivery system for nose to brain transport. From the stability 
studies it was observed that there is not significant changes in the physical property 
at room temperature and 5 ± 1°C. 
Summary & Conclusion 
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Present investigation, hence, led to successful nose to brain targeting of the 
hydrophilic drug almotriptan malate by its incorporation in chitosan biodegradable 
nanoparticles for the efficient therapeutic management of migraine. The future 
perspective of this project is that in-vivo studies should be done in this the optimised 
formulation and the optimized formulation can be combined with the free drug 
along with the penetration enhancers to enhance the release of the drug to provide 
quick action and prolonged release to treat mild to moderate migraine. All results 
of this research work provide useful information for future studies aiming at 
development of drug delivery formulation consisting of chitosan nanoparticles and 
with drug almotriptan malate for treatment of migraine. 
 
Bibliography 
 
 
Department of  Pharmaceutics   
BIBLIOGRAPHY 
 
 Abeer Ahmed Kassem1,2, Gihan Salah Labib, (2016), Flash Dissolving 
Sublingual Almotriptan Malate Lyotabs For Management Of Migraine, 
International Journal Pharm Sci, Vol 9, 125-131 
 Agnieszka Z. Wilczewska, Katarzyna Niemirowicz, Karolina H. 
Markiewicz, Halina Car (2011), Nanoparticles as drug delivery systems, 
Pharmacological Reports, 1021-1037 
 Anupam Kr Sachan, Swati Singh, (2014), Nanoparticles: Nasal Delivery 
Of Drugs, International Journal For Pharmaceutical Research Scholars, 
Vol 3,33-44 
 Girotra Priti Hansraj, Shailendra Kumar Singh, Pawan Kumar, (2015), 
Sumatriptan Succinate Loaded Chitosan Solid Lipid Nanoparticles for 
Enhanced Anti-Migraine Potential, International Journal of Biological 
Macromolecules, 467–476 
 Hansraj GP, Singh SK, Kumar P, Sumatriptan succinate loaded chitosan 
solid lipid nanoparticles for enhanced anti-migraine potential, Int J Biol 
Macromol, Vol 5,467-477 
 Hui-Chia Yang A & Min-Hsiung Hon (2010), The Effect Of The Degree 
Of Deacetylation Of Chitosan Nanoparticles And Its Characterization And 
Encapsulation Efficiency On Drug Delivery, Polymer-Plastics Technology 
And Engineering,1292-1296 
 Kumar Ganesh, Dhyani Archana(2015) Review Article on Targeted 
Polymeric Nanoparticles : An Overview, American Journal of Advanced 
Drug Delivery,196-215 
 Kushagri Singh, Abha Mishra, (2013), Water Soluble Chitosan 
Nanoparticle for The Effective Delivery Of Lipophilic Drugs: A Review, 
International Journal Of Applied Pharmaceutics, Vol 5, 1-6 
Bibliography 
 
 
Department of  Pharmaceutics   
 M.Shalini, M. M. Husnien Ali And P. K. Lakshmi, (2016), Formulation 
And Evaluation Of Elastic Niosomes Of Eletriptan Hydro bromide, 
International Journal Of Pharmaceutical Sciences And Research, Vol 04, 
1679, - 1685 
 Mohammadpour Dounighi N, Eskandari R, Avadi Mr, Zolfagharian H, 
Mir Mohammad Sadeghi A, Rezayat M, (2008), Preparation And In Vitro 
Characterization Of Chitosan Nanoparticles Containing Mesobuthus 
Eupeus Scorpion Venom As An Antigen Delivery System, The Journal Of 
Venomous Animals And Toxins Including Tropical Diseases, Vol 18, 
Issue 1, 44-52 
 Neha Gulati, Upendra Nagaich, And Shubhini A. Saraf,2013), Intranasal 
Delivery Of Chitosan Nanoparticles For Migraine Therapy,Scientia 
Pharmaceutia, 1167,1169 
 Pankaj Shard, Aruna Bhatia, Dipika Sharma(2014), Optimization And 
Effects Of Physico-Chemical Parameters On Synthesis Of Chitosan 
Nanoparticles By Ionic Gelation Technique, International Journal Of Drug 
Delivery Vol: 6, 58-63 
 Patil Satish K, Wagh Kalpesh , Mali Kamlesh, Baviskar Dheeraj , Jain 
Dinesh K, (2014), Development And Evaluation Of Solid Lipid 
Nanoparticles Containing Anti-Migraine Drug, World Journal Of 
Pharmaceutical Sciences, 1014-1021 
 R.R. Bhagwat And I.S. Vaidhya (2013), Novel Drug Delivery Systems: 
An Overview, International Journal Of Pharmaceutical Sciences And 
Research, 970-82 
 Sagar R. Mudshinge, Amol B. Deore, Sachin Patil, Chetan M. Bhalgat 
(2011), Nanoparticles: Emerging carriers for drug delivery, Saudi 
Pharmaceutical Journal,129-141 
Bibliography 
 
 
Department of  Pharmaceutics   
 Sagar S. Jadhav and Aparna V. Bhalerao (2013), Formulation And 
Characterization Of Chitosan Nanoparticles Loaded With Rizatriptan 
Benzoate, Der Pharmacia Lettre Vol 2 , 123-126 
 Satish K Mandlik, Saugat Adhikari And Nisharani S Ranpise(2014), 
Formulation And In-Vitro Characterization Of Chitosan Biodegradable 
Nanoparticles Of Zolmitriptan For Migraine Treatment, International 
Journal Of Comprehensive Pharmacy,Vol 04, 1-5 
 Sijumon Kunjachan, Sajan Jose1, Twan Lammers (2010), Understanding 
The Mechanism Of Ionic Gelation for Synthesis Of Chitosan 
Nanoparticles Using Qualitative Techniques, Asian Journal Of 
Pharmaceutics, 148-153 
 Sirisha Yella, Gopala Krishna Murthy Talasila And Srinivasa Rao 
Avanapu, (2016), Effect Of Various Excipients On Drug Release Of 
Almotriptan Orodispersible Tablets, Der Pharacia Lettre, Vol 8 ,84-94 
 Sovan Lal Pal, Utpal Jana, P. K. Manna, G. P. Mohanta, R. Manavalan, 
(2011), Nanoparticle: An Overview Of Preparation And Characterization, 
Journal Of Applied Pharmaceutical Science 01, Vol:06, 228-234 
 Sunena, Dinanath Mishra, Shailendra Kumar Singh, Anil Kumar 
(2016) Development and characterization of zolmitriptan loaded thiolated 
chitosan nanoparticles for intranasal drug delivery, The Pharma Innovation 
Journal, vol 5,19-23 
 Sunil A. Agnihotri, Nadagouda N. Mallikarjuna, Tejraj M. Aminabhavi 
(2004) Recent advances on chitosan-based micro- and nanoparticles in 
drug delivery, Journal of Controlled Release, 5-8 
 U. Viplova Prasad, M. Syam Bab1, B. Kalyana Ramu, (2012), 
Quantitative Assay Of Almotriptan Malate In Pure Drug And 
Pharmaceutical Preparations Using Simple And Convenient Visible 
Spectrophotometric Methods, International Journal Of Pharma Sciences 
And Research, Vol 3, 218-223 
Bibliography 
 
 
Department of  Pharmaceutics   
 Wim H De Jong, Paul Borm (2008) Drug delivery and nanoparticles: 
Applications and hazards, International Journal of Nanomedicine,133-149 
 Wim H De Jong1 And Paul Ja Borm, (2008), Drug Delivery  
And Nanoparticles: Applications And Hazards Int J Nanomedicine.; 3(2): 
133–149. 
 Yasir Mehmood*, Ayesha Tariq, Faheem Ahmad Siddiqui (2015), Brain 
Targeting Drug Delivery System: A Review, International Journal of Basic 
Medical Sciences and Pharmacy (Ijbmsp),32-40 
x,
s,
c*o
a4
*l
w
fD
IJ
.J
='.JgJ
.rc
6
rld
%ffi-%"M
%_#wrcw
ry&
ffi
a
w
*tffi
w
* EE
w
ffi
W
@M&
a'
,.fi
()
.D
4.
o]
r+(3
:-
r
=?
:
:^1-\
vfiI
:++
:
:>
:Z
:Z
t>
c\it,l-l
:>
:r0)
OJ Lrt
=(JJOJ
o.,
.1 d.
:F n"
JU
-: OJ
--tr +LTD
OJ
(l)a
e#6l\.) fuN) ,r-
=(D
g6-
.,.rD
=oJL,)rD TD
Efi
IDeH{r
A
H
='J
.D
z.
OJ
*.
=ol
fD
=
:,
O)
I:rC
rrl
:f
o(a
o)
il'a
(J\<
't
Ol
LO{'
no
6-
LA
rD()
**t
r([itl\'
o, I
=1,(Dl
€l
<l!r' Iq. IN, Irlrl(Dt
rlcl
=l
g
6
o
=oo-
a:
<
a't03
c
-o
aC
=
o
=:a1o
o
o()
T
3s
s1 *Itr
E%kf
ffit&
dtr&*H
%rc
w
!
-r./i
+ZE
fr=
- 
a-f
RaEO -,-i#o9+J
ea
=
<
'tt
o
:t(f
=!,
J
rD
€
6)(p
o,
at2
tD
=_:
a.
:r
roC
5
-rf0
€.
=.
o-
ro
.D
o
T
o
3
o,
